

03/37201

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 085 093 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
21.03.2001 Bulletin 2001/12

(51) Int. Cl.⁷: C12N 15/54, C12N 9/12,
C07K 16/40, C12Q 1/68,
C12Q 1/48, G01N 33/68

(21) Application number: 00307866.4

(22) Date of filing: 12.09.2000

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 20.09.1999 US 155029 P

(71) Applicant: NEW YORK UNIVERSITY
New York, NY 10012 (US)

(72) Inventors:

- Blumenberg, Miroslav
New York, New York 10016 (US)
- Gazel, Alix M.
11370, Leucate (FR)

(74) Representative:

Simpson, Alison Elizabeth Fraser et al
Urquhart-Dykes & Lord,
30 Welbeck Street
London W1G 8ER (GB)

(54) **Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof**

(57) The invention relates to novel polynucleotides and their encoded gene products that are expressed in skin cells, particularly keratinocytes, and methods of using the same. Specifically, the present invention provides polynucleotides encoding several novel protein kinases that are c-Jun N-terminal kinase kinases, i.e., MLK4, PAK4, PAK5 and YSK2. In addition, the invention provides methods of using the disclosed polynucleotides and their gene products in drug discovery, particularly in screening for drugs that can reduce ultraviolet light-induced damage of the skin, inflammation and psoriasis, and drugs that can enhance wound healing.

EP 1 085 093 A2

Description**1. Field of the Invention**

[0001] The invention provides novel polynucleotides, and their encoded gene products, that are expressed in skin cells, particularly keratinocytes, and methods of using the same. Specifically, the present invention relates to novel protein kinases that are c-Jun N-terminal kinase kinase kinases (JNKKKs). In addition, the invention provides methods of using the novel polynucleotides and their encoded products in drug discovery, particularly in screening for drugs that can reduce ultraviolet light-induced damage of the skin, inflammation and psoriasis, and drugs that can enhance wound healing.

2. Background of the Invention

[0002] Many extracellular signals, such as light, growth factors, cytokines and chemical or physical stresses, activate multi-tiered kinase cascades in the cytoplasm of cells. For example, a growth factor such as epidermal growth factor (EGF) will bind to its cognate receptor on the cell surface, thereby activating the intercellular protein ras, which is associated with the cytoplasmic portion of the cell surface receptor. Ras phosphorylates and thereby activates raf1, a mitogen-activated protein kinase kinase kinase (MAPKKK). Raf1 then induces (also by phosphorylation) the activation of mitogen-activated protein kinase kinases (MEKs), which in turn phosphorylate extracellular signal regulated kinases (ERKs). When phosphorylated, ERKs translocate to the nucleus where they phosphorylate and thus activate transcription factors such as stress activated protein kinase 1 (SAP1) and ternary complex factor Elk1. See, e.g., Fanger et al., 1997, Current Opin. Genet. Dev. 7:67-74.

[0003] Stress (such as heat and ultraviolet (UV) light) and cytokines (such as TNF- and IL-1) activate their own sets of kinase-kinase-kinases, termed JNKKKs. These, in turn, act on specific JNKs, which activate c-Jun-N terminal kinase (JNK) and p38. The last two kinases enter the nucleus, where they phosphorylate and activate transcription factors. See, e.g., Diene et al., 1997, PNAS 94:9687-92.

[0004] Most of the initial events in the cellular responses to different stresses have not been elucidated so far. However, it is clear that different extracellular signals activate different members of the JNKKK family. Thus, some JNKKKs are specifically responsive to TNF- α , others to osmotic shock, yet others to UV illumination. Diene et al., 1997, above; Raingeaud et al., 1995, J. Biol. Chem. 270:7420-6.

[0005] Skin cells such as keratinocytes are particularly susceptible to ultraviolet radiation damage. However, very little is known about how keratinocytes respond to ultraviolet radiation stress. Manipulation of keratinocyte responses to environmental stress could result in therapies for a wide variety of skin disorders, as well as cosmetic uses.

[0006] Therefore, there is a great need in the art to elucidate the components involved in keratinocyte signal transduction that can be used as targets for drug screening. Accordingly, this invention provides several novel JNKKKs expressed by keratinocytes and involved in the cellular response to ultraviolet radiation, and uses thereof.

3. Summary of the Invention

[0007] The present invention relates to polynucleotide molecules having nucleotide sequences that encode portions of several novel JNKKK gene products including an MLK4 kinase, a PAK4 kinase, a PAK5 kinase, and a YSK2 kinase, as well as the amino acid sequences encoded by these polynucleotide sequences. The present invention further relates to polynucleotide molecules having nucleotide sequences that encode a PAK5 kinase.

[0008] In one aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human MLK4 gene product. In a preferred embodiment, the portion of the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:1.

[0009] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:1. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:2.

[0010] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned MLK4-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the MLK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human MLK4 gene product or MLK4-related homologous polypeptide of the present invention. In a specific though non-limiting embodiment, the present invention provides a polynucleotide molecule consisting of a nucleotide sequence encoding a peptide fragment consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:2.

[0011] In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK4 gene. In a preferred embodiment, the portion of the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:3.

[0012] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:4.

[0013] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK4-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the PAK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK4 gene product or PAK4-related homologous polypeptide of the present invention. In a specific though non-limiting embodiment, the present invention provides a polynucleotide molecule consisting of a nucleotide sequence encoding a peptide fragment consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:4.

[0014] In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK5 gene product. In a preferred embodiment, the portion of the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:6 comprises the nucleotide sequence of SEQ ID NO:5.

[0015] In another aspect, invention provides an isolated polynucleotide molecule comprising a portion of the nucleotide sequence of the human PAK5 gene, which portion encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:8. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:8 comprises the nucleotide sequence of SEQ ID NO:7.

[0016] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:7. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:8.

[0017] In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding the complete human PAK5 gene product having the amino acid sequence of SEQ ID NO:10. In a preferred embodiment, the polynucleotide molecule comprises the nucleotide sequence of SEQ ID NO:9 from nt 199 to nt 2244, which represents the ORF of the cDNA. In another non-limiting embodiment, the isolated polynucleotide molecule encoding the complete human PAK5 gene product comprises the nucleotide sequence of the ORF of SEQ ID NO:11 from nt 6125 to nt 17,433.

[0018] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:9 or SEQ ID NO:11.

[0019] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK5-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the PAK5-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK5 gene product or PAK5-related homologous polypeptide of the present invention.

[0020] In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human YSK2 gene product. In a preferred embodiment, the portion of the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:12.

[0021] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:12. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:13.

[0022] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned YSK2-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the YSK2-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human YSK2 gene product or YSK2-related homologous polypeptide of the present invention. In a specific though non-limiting embodiment, the present invention provides a polynucleotide molecule consisting of a nucleotide sequence encoding a peptide fragment consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:13.

[0023] The present invention further provides compositions and methods for cloning and expressing any of the polynucleotide molecules of the present invention, including cloning vectors and expression vectors comprising any of the polynucleotide molecules of the present invention, as well as transformed host cells and novel strains or cell lines

derived therefrom comprising any of the polynucleotide molecules, cloning vectors or expression vectors of the present invention. In a non-limiting embodiment, the present invention provides a recombinant expression vector comprising a polynucleotide molecule of the present invention in operative association with one or more regulatory elements for expression of the polynucleotide molecule.

5 [0024] Also provided by the present invention is a substantially purified or isolated polypeptide encoded by a polynucleotide molecule of the present invention. In a specific though non-limiting embodiment, the polypeptide is a portion of a human MLK4 gene product comprising the amino acid sequence of SEQ ID NO:2. In another specific though non-limiting embodiment, the polypeptide is a portion of a human PAK4 gene product comprising the amino acid sequence of SEQ ID NO:4. In another specific though non-limiting embodiment, the polypeptide is a portion of a human PAK5
10 gene product, comprising the amino acid sequence of either SEQ ID NO:6 or SEQ ID NO:8, or is the entire human PAK5 gene product comprising the amino acid sequence of SEQ ID NO:10. In another specific though non-limiting embodiment, the polypeptide is a portion of a YSK2 gene product, comprising the amino acid sequence of SEQ ID NO:13.

[0025] The present invention also provides substantially purified or isolated polypeptides that are homologous to the portions of the human MLK4, PAK 4, PAK5 and YSK2 gene products of the present invention. The present invention also provides a substantially purified or isolated polypeptide that is homologous to the complete human PAK5 gene product of the present invention. The present invention further provides substantially purified or isolated peptide fragments of the MLK4, PAK4, and PAK5 gene products of the present invention, and substantially purified or isolated peptide fragments of the YSK2 gene product of the present invention that have the first six amino acids of SEQ ID NO:13.

20 [0026] The present invention also provides a method of preparing a substantially purified or isolated portion of a human MLK4, PAK4, PAK5 or YSK2 gene product, or a substantially purified or isolated human PAK5 gene product, or a homologous peptide, or peptide fragment of the present invention, comprising culturing host cells transformed with a polynucleotide molecule or vector of the present invention under conditions conducive to the expression therefrom of the polypeptide or peptide fragment of the invention, and recovering the polypeptide or peptide fragment in substantially
25 purified or isolated form from the cell culture.

[0027] Also provided are antibodies specific for the MLK4, PAK4, PAK5 or YSK2 gene product, homologous peptide, or peptide fragment of the present invention, and methods of detecting the MLK4, PAK4, PAK5 or YSK2 gene product, homologous peptide, or peptide fragment of the present invention in a sample. Still another aspect of the invention provides methods of identifying compounds that bind to the MLK4, PAK4, PAK5 or YSK2 gene product, homologous
30 peptide, or peptide fragment of the present invention.

[0028] The present invention also provides methods of detecting an MLK4, PAK4, PAK5 or YSK2-related polynucleotide in a sample, comprising contacting the sample with a compound that binds to and forms a complex with the particular polynucleotide for a period of time sufficient to form the complex, and detecting the complex, so that if a complex is detected, the MLK4, PAK4, PAK5 or YSK2-related polynucleotide, respectively, is detected. In a nonlimiting
35 embodiment, the method comprises contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the particular polynucleotide under such hybridization conditions, and amplifying the annealed polynucleotides, so that if a particular polynucleotide is amplified, the MLK4, PAK4, PAK5 or YSK2-related polynucleotide, respectively, is detected.

[0029] The invention further provides a method of screening for compounds that affect the cellular levels of a JNKKK gene product, comprising: (a) applying a test compound to a test sample; (b) determining the cellular levels of at least one gene product in the test sample, wherein the gene product is from a gene comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11 and 12; and (c) comparing the levels of the gene product in the test sample with that in a reference sample; wherein a specific change in the cellular levels of the gene product in the test sample as compared to the reference sample indicates that the test compound affects the
45 cellular levels of gene product from a JNKKK gene. In a preferred embodiment, the method further comprises the step of applying a stress event to the test sample and determining the effect of the test compound on the response of the test sample to the stress event.

[0030] The invention further provides a method of screening for compounds that affect the expression of a gene that encodes a JNKKK gene product, comprising: (a) applying a test compound to a test sample; (b) determining the expression level of at least one gene in cells of the test sample, wherein the gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11 and 12; and (c) comparing the expression level of the gene in the test sample with that in a reference sample; wherein a specific change in the expression of the gene in the test sample as compared to the reference sample indicates that the test compound affects the expression of the gene. In a preferred embodiment, the method further comprises the step of applying a stress event to the test sample
50 and determining the effect of the test compound on the gene expression response of the test sample to the stress event.

[0031] Still another aspect of the invention provides a method of screening for compounds that affect the activity of a JNKKK gene product, the method comprising: (a) applying a test compound to a test sample; and (b) determining the activity of a JNKKK gene product in the test sample versus a reference sample, wherein the JNKKK gene product com-

prises an amino acid sequence selected from the group consisting of: SEQ ID NOS: 2, 4, 6, 8, 10 and 13; wherein a test compound that alters the JNKKK gene product activity in the test sample as compared to the reference sample is identified as a compound that affects the activity of the JNKKK gene product. In a preferred embodiment, the method further comprises the step of applying a stress event to the test sample and determining the effect of the test compound on the response of the test sample to the stress event.

4. Brief Description of the Figures

[0032]

Figure 1 is a schematic diagram illustrating the structure of the PAK5 gene.

Figure 2 is a Northern Blot illustrating the tissue-specific expression of MLK4, PAK4 and PAK5 genes. Messenger RNA was isolated from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas, run on a denaturing gel in the indicated lanes, and blotted to a membrane. The same blot was sequentially hybridized (after stripping between hybridizations) to labeled 150 base pair probes specific for MLK4, PAK4 and PAK5.

Figure 3 shows the induction of YSK2 and PAK5 genes in response to ultraviolet radiation. Figure 3A is a Northern blot of mRNA from keratinocytes untreated (control) or treated (control) with UV-C radiation for 5 days. The blot was hybridized to a 150 base pair probe specific for the YSK2 gene. Figure 3B shows a differential display experiment designed to examine any change in expression levels of the PAK4 and PAK5 genes in response to UV-A light. Keratinocytes were exposed to UV-A light for 0, 6 or 24 hours, harvested and mRNA analyzed. Bands corresponding the PAK4 and PAK5 message are indicated.

5. Detailed Description of the Invention

[0033] The present invention relates to identification and characterization of polynucleotide molecules expressed in skin keratinocytes, which polynucleotide molecules encode JNKKK polypeptides. Because the kinase domains of JNKKKs are conserved in sequence, primers can be designed for reverse transcription-polymerase chain reaction (RT-PCR) detection of virtually all the JNKKKs expressed by a cell or cell type. In one embodiment, the primer pair 5'-ATGCA(CA)CANGA(CT)AT(ACT)AA(AG)-3' (SEQ ID NO:14) (forward) and 5'-GCNAC(CT)TCNGGNGCCATCCA-3' (SEQ ID NO:15) (reverse) can be used to detect novel JNKKKs. The product of using the primer pair is a common 150 bp segment. As discussed below in the Example sections, a primer pair was used to screen human epidermal keratinocyte mRNA, and polynucleotides encoding several novel JNKKKs were discovered. In addition, the present invention relates to the discovery that the JNKKKs encoded by these polynucleotides are involved in the cellular response to stress such as ultraviolet (UV) light. By way of example, the invention is described in the sections below for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the MLK4 open reading frame (ORF) (SEQ ID NO:1); for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the PAK4 ORF (SEQ ID NO:3); for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the PAK5 ORF (SEQ ID NO:5); for another isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the PAK5 gene (SEQ ID NO:7); for an isolated polynucleotide molecule comprising the nucleotide sequence of the cDNA encoding the PAK5 gene product (SEQ ID NO:9, ORF from nt 199-2244); for an isolated polynucleotide molecule comprising the nucleotide sequence of the PAK5 gene (SEQ ID NO:11, ORF from nt 6125-17433); and for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the YSK2 ORF (SEQ ID NO:12).

5.1. Polynucleotide Molecules

[0034] As used herein, the terms "polynucleotide molecule," "polynucleotide sequence," "coding sequence" "open-reading frame (ORF)", and the like, are intended to refer to both DNA and RNA molecules, which can either be single-stranded or double-stranded. A coding sequence or ORF can include but is not limited to prokaryotic sequences, cDNA sequences, genomic DNA sequences, and chemically synthesized DNA and RNA sequences. A "gene product" is intended to refer to a product encoded by a gene, including the transcribed RNA message (including exons and introns), the spliced messenger RNA (mRNA), and the translated protein product encoded by the respective mRNA.

[0035] Production and manipulation of the polynucleotide molecules and oligonucleotide molecules disclosed herein are within the skill in the art and can be carried out according to recombinant techniques described, among other places, in Maniatis et al. 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel et al., 1989, Greene Publishing Associates & Wiley Interscience, NY; Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Innis et al. (eds), 1995, PCR Strategies, Academic Press, Inc., San Diego; and Erlich (ed), 1992, PCR Technology, Oxford University Press, New York, all of which are incorporated herein by reference.

5.1.1. MLK4-related Polynucleotide Molecules

[0036] The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human MLK4-related gene product. In a preferred embodiment, the portion of the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:1.

[0037] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:1. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:1, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code (i.e., a degenerate variant); or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:1, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK), and which hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2XSSC/0.1% SDS at 42°C (see Ausubel et al. (eds.), 1989, Current Protocols in Molecular Biology, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3), and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS at 68°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of the nucleotide sequence of SEQ ID NO:1, and is useful in practicing the invention.

[0038] As used herein, an MLK4-related polynucleotide molecule is "useful in practicing the invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the MLK4 gene product from a eukaryotic cell; or (ii) can detect the presence of the MLK4 transcript in a test sample; or (iii) can enable a method for altering the regulation or expression of the endogenous MLK4 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide sequence of the MLK4 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring MLK4 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated MLK4 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

[0039] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:2. As used herein to refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a portion of an MLK4 gene product from a human, the term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:2, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, wherein the resulting amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:2 wherein amino acid sequence identity is determined by any standard amino acid sequence identity algorithm, such as, e.g., BLASTP (GENBANK), where the resulting polypeptide is useful in practicing the invention. Conservative amino acid substitutions are well known in the art. Rules for making such substitutions include those described by Dayhof, M.D., 1978, Nat. Biomed. Res. Found., Washington, D.C., Vol. 5, Sup. 3, among others. More specifically, conservative amino acid substitutions are those that generally take place within a family of amino acids that are related in the acidity, or polarity of their side chains. Genetically encoded amino acids are generally divided into four groups: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan and tyrosine are also jointly classified as aromatic amino acids. One or more replacements within any particular group, e.g., of a leucine with an isoleucine or valine, or of an aspartate with a glutamate, or of a threonine with a serine, or of any other amino acid residue with a structurally related amino acid residue, e.g., an amino acid residue with similar acidity, or polarity or with similarity in a combination thereof, will generally have an insignificant effect on the function of the polypeptide.

[0040] As used herein, an MLK4-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against an MLK4 gene product from a eukaryotic, preferably mammalian, and most

preferably human cell or tissue, or to screen for compounds that modulate MLK4 activity or production in such a cell or tissue.

[0041] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned MLK4-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of an MLK4-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of the nucleotide sequence of SEQ ID NO:1 or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, of the length of said nucleotide sequence, and that is useful in practicing the invention, as usefulness is defined above for MLK4-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the MLK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human MLK4 gene product of the present invention. A "peptide fragment" of an MLK4-related polypeptide refers to a polypeptide consisting of a subsequence of SEQ ID NO:2, which sub-sequence is useful in practicing the invention, as usefulness is defined above for MLK4-related polypeptides. As used herein, a "peptide fragment" is preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

[0042] The MLK4-related polynucleotide molecules disclosed herein can be used to express a portion of the human MLK4 gene product, to detect expression of an MLK4 gene product in a cell type or tissue, to prepare novel cell lines in which the MLK4 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative MLK4, e.g., by mutating the ATP binding site, using well known techniques (see, e.g., Abo et al., below), and to identify MLK4 homolog genes in eukaryotic species other than humans, and particularly in other mammalian species, using known techniques. Thus, the present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding an MLK4 homolog gene product. As used herein, an "MLK4 homolog gene product" is defined as a gene product encoded by an MLK4 homolog gene which, in turn, is defined as a gene from a different eukaryotic species other than human and which is recognized by those of skill in the art as a homolog of the human MLK4 gene based on a degree of sequence identity at the amino acid level of greater than about 70%.

[0043] Methods for identifying polynucleotide clones containing MLK4 homolog genes are known in the art. For example, a polynucleotide molecule comprising a portion of the human MLK4 ORF can be detectably labeled and used to screen a genomic library constructed from DNA derived from the organism of interest. The stringency of the hybridization conditions can be selected based on the relationship of the reference organism to the organism of interest. Requirements for different stringency conditions are well known to those of skill in the art, and such conditions will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. Genomic DNA libraries can be screened for MLK4 homolog gene coding sequences using the techniques set forth, among other places, in Benton and Davis, 1977, Science 196:180, for bacteriophage libraries, and in Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. USA, 72:3961-3965, for plasmid libraries, which publications are incorporated herein by reference. Polynucleotide molecules having nucleotide sequences known to include a portion of the MLK4 ORF, as shown in SEQ ID NO:1, or oligonucleotide molecules representing portions thereof, can be used as probes in these screening experiments. Alternatively, oligonucleotide probes can be synthesized that correspond to nucleotide sequences deduced from the amino acid sequence of the purified MLK4 gene product.

[0044] Clones identified as containing MLK4 homolog gene coding sequences can be tested for appropriate biological function. For example, the clones can be subjected to sequence analysis in order to identify a suitable reading frame, as well as initiation and termination signals. The cloned DNA sequence can then be inserted into an appropriate expression vector which is then transformed into cells (such as human cells) that have been rendered MLK4 null to test for complementation. Transformed host cells can then be analyzed for MLK4 signal transduction.

5.1.2. PAK4-related Polynucleotide Molecules

[0045] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK4 gene product. In a preferred embodiment, the portion of the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:3.

[0046] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:3, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:3, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK) and hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid

sequence of SEQ ID NO:4 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:4 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1 % SDS at 68°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3, and is useful in practicing the invention.

[0047] As used herein, a PAK4-related polynucleotide molecule is "useful in practicing the invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the PAK4 gene product from a eukaryotic cell; or (ii) can detect the presence of the PAK4 transcript in a test sample; or (iii) can enable a method for altering the regulation or expression of the endogenous PAK4 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide sequence of the PAK4 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring PAK4 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated PAK4 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

[0048] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:4. As used herein to refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a PAK4 gene product from a human cell, the term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:4, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, as conservative amino acid substitutions are defined above, wherein the resulting amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:4, as determined, e.g., using the BLASTP algorithm (GENBANK), where the resulting polypeptide is useful in practicing the invention.

[0049] As used herein, a PAK4-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against a PAK4 gene product from a eukaryotic, preferably mammalian, and most preferably human, cell or tissue, or to screen for compounds that modulate PAK4 activity or production in such a cell or tissue.

[0050] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK4-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a PAK4-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of SEQ ID NO:3 or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, of the length of said nucleotide sequence, and that is useful in practicing the invention, as usefulness is defined above for PAK4-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the PAK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK4 gene product of the present invention. A "peptide fragment" of a PAK4-related polypeptide refers to a polypeptide consisting of a sub-sequence of SEQ ID NO:4, which sub-sequence is useful in practicing the invention, as usefulness is defined above for PAK4-related polypeptides. Peptide fragments of the invention are preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

[0051] The PAK4-related polynucleotide molecules disclosed herein can be used to express a portion of the human PAK4 gene product, to detect expression of a PAK4 gene product in a cell type or tissue, to prepare novel cell lines in which the PAK4 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative PAK4, e.g., by mutating the ATP binding site, using well known techniques (see, e.g., Abo et al., below), and to identify PAK4 homolog genes in eukaryotic species other than humans, and particularly in other mammalian species, using known techniques. Thus, the present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK4 homolog gene product. As used herein, a "PAK4 homolog gene product" is defined as a gene product encoded by a PAK4 homolog gene which, in turn, is defined as a gene from a different eukaryotic species other than human and which is recognized by those of skill in the art as a homolog of the human PAK4 gene based on a degree of sequence identity at the amino acid level of greater than about 70%. Methods for identifying polynucleotide clones containing PAK4 homolog genes are known in the art as described above.

5.1.3. PAK5-related Polynucleotide Molecules

[0052] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK5 gene product. In a preferred embodiment, the portion of the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:6 comprises the nucleotide sequence of SEQ ID NO:5. In another preferred embodiment, the portion of the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:8. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:8 comprises the nucleotide sequence of SEQ ID NO:7. Still another non-limiting embodiment of the invention is the sequence of any one of the exons of the PAK5 genomic DNA (see SEQ ID NO:7). A further non-limiting embodiment of the invention is the sequence of any one of the introns of the PAK5 genomic DNA.

[0053] The present invention further provides an isolated polynucleotide molecule comprising the cDNA nucleotide sequence of SEQ ID NO:9 (ORF from nt 199-2244) encoding a complete human PAK5 gene product. The present invention further provides an isolated polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:11 (ORF from nt 6125-17433), which represents the human PAK5 gene.

[0054] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising a nucleotide sequence encoding a portion of a PAK5 gene product of the present invention. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO:11, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:7, or to the ORF of SEQ ID NO:9 or SEQ ID NO:11, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK), and hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:10 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:10 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:7, or the ORF of SEQ ID NO:9 or SEQ ID NO:11, and is useful in practicing the invention.

[0055] As used herein, a PAK5-related polynucleotide molecule is "useful in practicing the invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the PAK5 gene product from a eukaryotic cell; or (ii) can detect the presence of the PAK5 transcript in a test sample; or (iii) can enable a method for altering the regulation or expression of the endogenous PAK5 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide sequence of the PAK5 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring PAK5 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated PAK5 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

[0056] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10. As used herein to refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a PAK5 gene product from a human cell, the term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, as conservative amino acid substitutions are defined above, wherein the resulting amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, as determined, e.g., using the BLASTP algorithm (GENBANK), and where the resulting polypeptide is useful in practicing the invention.

[0057] As used herein, a PAK5-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against a PAK5 gene product from a eukaryotic, preferably mammalian, and most preferably

human, cell or tissue, or to screen for compounds that modulate PAK5 activity or production in such a cell.

[0058] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK5-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a PAK5-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 (from nt 199-2244) or SEQ ID NO:11 (from nt 6125-17433) or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, the length of said nucleotide sequence, and that is useful in practicing the invention, as usefulness is defined above for PAK5-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the PAK5-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK5 gene product of the present invention. A "peptide fragment" of a PAK5-related polypeptide refers to a polypeptide consisting of a sub-sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, which sub-sequence is useful in practicing the invention, as usefulness is defined above for PAK5-related polypeptides. Peptide fragments of the invention are preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

[0059] The PAK5-related polynucleotide molecules disclosed herein can be used to express a portion of the PAK5 gene product, to detect expression of a PAK5 gene in a cell or tissue, to prepare novel cell lines in which the PAK5 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative PAK5 by mutating the ATP binding site using well known techniques (see, e.g., Abo et al., below), and to identify PAK5 homolog genes in other eukaryotic species or cell types using standard techniques. Thus, the present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK5 homolog gene product. As used herein, a "PAK5 homolog gene product" is defined as a gene product encoded by a PAK5 homolog gene which, in turn, is defined as a gene from a eukaryotic species other than human, and which is recognized by those of skill in the art as a homolog of the human PAK5 gene based on a degree of sequence identity at the amino acid level of greater than about 80%. Methods for identifying polynucleotide clones containing PAK5 homolog genes are known in the art, as described above.

5.1.4. YSK2-related Polynucleotide Molecules

[0060] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a YSK2 gene product from a human cell. In a preferred embodiment, the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:12.

[0061] The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising a nucleotide sequence encoding a portion of the YSK2 gene product of the present invention. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:12, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:12, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK), and hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:13 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, above), and encodes at least the first 6 amino acid residues of SEQ ID NO:13 and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:13 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1 % SDS at 68°C (Ausubel et al., 1989, above), and encodes at least the first 6 amino acid residues of SEQ ID NO:13, and is useful in practicing the invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:12, and encodes at least the first 6 amino acid residues of SEQ ID NO:13, and is useful in practicing the invention.

[0062] As used herein, a YSK2-related polynucleotide molecule is "useful in practicing the invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the YSK2 gene product from a eukaryotic cell; or (ii) can detect the presence of the YSK2 transcript in a test sample; or (iii) can enable a method for altering the regulation or expression of the endogenous YSK2 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide

sequence of the YSK2 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring YSK2 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated YSK2 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

[0063] The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:13. As used herein to refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a YSK2 gene product from a human cell, the term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:13, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, as conservative amino acid substitutions are defined above, wherein the resulting amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:13, as determined, e.g., using the BLASTP algorithm (GENBANK), and which encodes at least the first 6 amino acid residues of SEQ ID NO:13 and where the resulting polypeptide is useful in practicing the invention.

[0064] As used herein, a YSK2-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against a YSK2 gene product from a eukaryotic, preferably mammalian, and most preferably human, cell or tissue, or to screen for compounds that modulate YSK2 activity or production in such a cell or tissue.

[0065] The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned YSK2-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a YSK2-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of SEQ ID NO:12 or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, the length of said nucleotide sequence, and encoding at least the first 6 amino acid residues of SEQ ID NO:13 and that is useful in practicing the invention, as usefulness is defined above for YSK2-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the YSK2-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a YSK2 gene product of the present invention. A "peptide fragment" of a YSK2-related polypeptide refers to a polypeptide consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:13, yet contains the sequence of residues 1 to 6 of SEQ ID NO:13, and which sub-sequence is useful in practicing the invention, as usefulness is defined above for YSK2-related polypeptides. Peptide fragments of the invention are preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

[0066] The YSK2-related polynucleotide molecules disclosed herein can be used to express a portion of the human YSK2 gene product, to detect expression of a YSK2 gene product in a cell type or tissue, to prepare novel cell lines in which the YSK2 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative YSK2 by mutating the ATP binding site using well known techniques (see, e.g., Abo et al., below), and to identify YSK-2 homolog genes in other eukaryotic species or cell types, as described above. As used herein, a "YSK2 homolog gene product" is defined as a gene product encoded by a YSK2 homolog gene which, in turn, is defined as a gene from a eukaryotic species other than human, and which is recognized by those of skill in the art as a homolog of the human YSK2 gene based on a degree of sequence identity at the amino acid level of greater than about 80%. Methods for identifying polynucleotide clones containing YSK2 homolog genes are known in the art, as described above.

5.2. Oligonucleotide Molecules

[0067] The present invention further provides oligonucleotide molecules that hybridize to any of the aforementioned polynucleotide molecules of the present invention, or that hybridize to a polynucleotide molecule having a nucleotide sequence that is the complement of any of the aforementioned polynucleotide molecules of the present invention. Such oligonucleotide molecules are preferably at least about 10 nucleotides in length, and more preferably at least about 20 nucleotides in length, and can hybridize to one or more of the aforementioned polynucleotide molecules under moderately or highly stringent conditions. For shorter oligonucleotide molecules, an example of highly stringent conditions includes washing in 6xSSC/0.5% sodium pyrophosphate at about 37°C for ~14-base oligos, at about 48°C for ~17-base oligos, at about 55°C for ~20-base oligos, and at about 60°C for ~23-base oligos. For longer oligonucleotide molecules (i.e., greater than about 100 nts), examples of moderately and highly stringent conditions are described in Section 5.1.1 above for homologous polynucleotide molecules. Hybridization conditions can be appropriately adjusted as known in the art, depending upon the particular oligonucleotide molecules utilized.

[0068] In a preferred embodiment, an oligonucleotide molecule of the present invention hybridizes under highly stringent conditions to a polynucleotide molecule having a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11 or 12, or to a polynucleotide molecule having a nucleotide sequence that is the comple-

ment of a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11 or 12.

[0069] The oligonucleotide molecules of the present invention are useful for a variety of purposes, including as primers in amplifying a MLK4, PAK4, PAK5 or YSK2 gene product-encoding polynucleotide molecule, or as anti-sense molecules useful in regulating expression of JNKKK genes and gene products. Amplification can be carried out using suitably designed oligonucleotide molecules in conjunction with standard techniques, such as the polymerase chain reaction (PCR), although other amplification techniques known in the art, e.g., the ligase chain reaction, can also be used. For example, for PCR, a mixture comprising suitably designed primers, a template comprising the nucleotide sequence to be amplified, and appropriate PCR enzymes and buffers, is prepared and processed according to standard protocols to amplify a specific MLK4-, PAK4-, PAK5-, or YSK2-related polynucleotide sequence of the template.

5.3. Recombinant Expression Systems

5.3.1. Expression Vectors

[0070] The present invention further provides recombinant cloning vectors and recombinant expression vectors comprising a polynucleotide molecule of the present invention, which vectors are useful in cloning or expressing said polynucleotide molecules, including polynucleotide molecules comprising portions of the MLK4, PAK4, PAK5 or YSK2 ORFs, or the entire PAK5 ORF, of the present invention.

[0071] The following description is intended to apply to all of the aforementioned polynucleotide molecules and polypeptides of the present invention, including polynucleotide molecules comprising portions of the MLK4, PAK4, PAK5 or YSK2 ORFs, the entire PAK5 ORF, and their gene products, and all homologous polynucleotide molecules, homologous polypeptides, substantial portions of such polynucleotide molecules, and peptide fragments of such gene products and polypeptides, as defined above, unless otherwise indicated.

[0072] Recombinant vectors of the present invention, particularly expression vectors, are preferably constructed so that the coding sequence for the polynucleotide molecule of the present invention is in operative association with one or more regulatory elements necessary for transcription and translation of the coding sequence to produce a polypeptide. As used herein, the term "regulatory element" includes but is not limited to nucleotide sequences of inducible and noninducible promoters, enhancers, operators and other elements known in the art that serve to drive and/or regulate expression of polynucleotide coding sequences. Also, as used herein, the coding sequence is in "operative association" with one or more regulatory elements where the regulatory elements effectively regulate and allow for the transcription of the coding sequence or the translation of its mRNA, or both.

[0073] Typical plasmid vectors that can be engineered to contain a polynucleotide molecule of the present invention include pCR-Blunt, pCR2.1 (Invitrogen), and pGEM3Zf (Promega), among many others. Additionally, vectors particularly designed for expression in eukaryotic cells, such as mammalian cells, are commercially available from Invitrogen (San Diego, CA) and Promega.

[0074] The regulatory elements of these vectors can vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements can be used. Non-limiting examples of transcriptional regulatory regions or promoters for bacteria include the β -gal promoter, the T7 promoter, the TAC promoter, lambda left and right promoters, trp and lac promoters, and the trp-lac fusion promoters. Non-limiting examples of transcriptional regulatory regions or promoters for eukaryotic cells include viral regulatory regions such as, for example, the SV40 early promoter region, the herpes thymidine kinase promoter, the cytomegalovirus (CMV) promoter, and the mouse mammary tumor virus control region, tissue specific or inducible promoters from endogenous eukaryotic genes such as, for example, the albumin promoter, myosin light chain-2 promoter, the insulin promoter, the metallothionein promoter, and fungal promoters such as, for example, the gal 4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, and the mating factor promoters, to name just a few.

[0075] Methods are well-known in the art for constructing recombinant vectors containing particular coding sequences in operative association with appropriate regulatory elements, and any of these can be used to practice the present invention. These methods include in vitro recombinant techniques, synthetic techniques, and in vivo genetic recombination. See, e.g., the techniques described in Maniatis et al., 1989, above; Ausubel et al., 1989, above; Sambrook et al., 1989, above; Innis et al., 1995, above; and Erlich, 1992, above.

[0076] Fusion protein expression vectors can be used to express an MLK4, PAK4, PAK5 or YSK2 gene product-fusion protein. The purified fusion protein can be used to raise antisera against the MLK4, PAK4, PAK5 or YSK2 gene product, to study the biochemical properties of the MLK4, PAK4, PAK5 or YSK2 gene product, to engineer the MLK4, PAK4, PAK5 or YSK2 fusion proteins with different biochemical activities, or to aid in the identification or purification of the expressed MLK4, PAK4, PAK5 or YSK2 gene product in recombinant expression systems. Possible fusion protein expression vectors include but are not limited to vectors incorporating sequences that encode β -galactosidase and trpE fusions, maltose binding protein fusions, glutathione-S-transferase fusions and polyhistidine fusions (carrier regions).

[0077] MLK4, PAK4, PAK5 or YSK2 fusion proteins can be engineered to comprise a region useful for purification.

For example, MLK4-, PAK4-, PAK5- and YSK2-maltose-binding protein fusions can be purified using amylose resin; MLK4-, PAK4-, PAK5- and YSK2-glutathione-S-transferase fusion proteins can be purified using glutathione-agarose beads; and MLK4-, PAK4-, PAK5- and YSK2-polyhistidine fusions can be purified using divalent nickel resin. Alternatively, antibodies against a carrier protein or peptide can be used for affinity chromatography purification of the fusion protein. For example, a nucleotide sequence coding for the target epitope of a monoclonal antibody can be engineered into the expression vector in operative association with the regulatory elements and situated so that the expressed epitope is fused to the MLK4, PAK4, PAK5 or YSK2 polypeptide. For example, a nucleotide sequence coding for the FLAG™ epitope tag (International Biotechnologies Inc.), which is a hydrophilic marker peptide, can be inserted by standard techniques into the expression vector at a point corresponding to the amino or carboxyl terminus of the MLK4, PAK4, PAK5 or YSK2 polypeptide. The expressed MLK4, PAK4, PAK5 or YSK2 polypeptide-FLAG™ epitope fusion product can then be detected and affinity-purified using commercially available anti-FLAG™ antibodies.

[0078] The expression vector encoding the MLK4, PAK4, PAK5 or YSK2 fusion protein can also be engineered to contain sequences that encode specific protease cleavage sites so that the expressed MLK4, PAK4, PAK5 or YSK2 polypeptide can be released from the carrier region or fusion partner by treatment with a specific protease. For example, the fusion protein vector can include DNA sequences encoding thrombin or factor Xa cleavage sites, among others.

[0079] A signal sequence upstream from and in reading frame with the MLK4, PAK4, PAK5 or YSK2 ORF can be engineered into the expression vector by known methods to direct the trafficking and secretion of the expressed gene product. Non-limiting examples of signal sequences include those from α factor, immunoglobulins, outer membrane proteins, penicillinase, and T-cell receptors, among others.

[0080] To aid in the selection of host cells transformed or transfected with cloning or expression vectors of the present invention, the vector can be engineered to further comprise a coding sequence for a reporter gene product or other selectable marker. Such a coding sequence is preferably in operative association with regulatory element coding sequences, as described above. Reporter genes that can be useful in the invention are well known in the art and include those encoding green fluorescent protein, luciferase, xylE, and tyrosinase, among others. Nucleotide sequences encoding selectable markers are well known in the art, and include those that encode gene products conferring resistance to antibiotics or anti-metabolites, or that supply an auxotrophic requirement. Examples of such sequences include those that encode resistance to methotrexate, G418 or mycophenolic acid, among many others.

5.3.2. Host Cells

[0081] The present invention further provides transformed host cells comprising a polynucleotide molecule or recombinant vector of the invention, and novel strains or cell lines derived therefrom. Host cells useful in the practice of the invention are preferably human cells, although other eukaryotic cells or prokaryotic cells can also be used. Such other transformed host cells typically include but are not limited to microorganisms, such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA vectors, or yeast transformed with recombinant vectors, among others.

[0082] Appropriate host cells can be chosen that modify and process the gene product in the specific fashion desired. Different host cells have characteristic mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation) of proteins. For example, expression in a bacterial system can be used to produce an unglycosylated protein product. Expression and secretion in yeast can produce a glycosylated protein product. Expression in mammalian cells can be used to ensure "native" processing of a protein product. Further, different vector/host expression systems can affect processing reactions to different degrees.

[0083] Preferred bacterial cells as host cells are strains of *E. coli*, e.g., for cloning or expression purposes. A strain of *E. coli* adapted to growth in culture and for cloning techniques can typically be used, such as, e.g., the DH5 α strain, which is available either from the American Type Culture Collection (ATCC), Rockville, MD, USA (Accession No. 31343) or from commercial sources (Stratagene). Preferred eukaryotic host cells include human cells, and in particular keratinocytes, although other mammalian cells and yeast cells or insect cells can also be utilized effectively.

[0084] The recombinant expression vector of the invention is preferably transformed or transfected into one or more host cells of a substantially homogeneous culture of cells. The expression vector is generally introduced into host cells in accordance with known techniques, such as, e.g., by protoplast transformation, calcium phosphate precipitation, calcium chloride treatment, microinjection, electroporation, transfection by contact with a recombined virus, liposome-mediated transfection, DEAE-dextran transfection, transduction, conjugation, or microprojectile bombardment. Selection of transformants can be conducted by standard procedures, such as by selecting for cells expressing a selectable marker, e.g., antibiotic resistance, associated with the recombinant vector, as described above.

[0085] Once the expression vector is introduced into the host cell, the integration and maintenance of the MLK4-, PAK4-, PAK5- or YSK2-related coding sequence, either in the host cell chromosome or episomally, can be confirmed by standard techniques, e.g., by Southern hybridization analysis, restriction enzyme analysis, PCR analysis, including reverse transcriptase PCR (rt-PCR), or by immunological assay to detect the expected gene product. Host cells con-

taining and/or expressing the recombinant MLK4-, PAK4-, PAK5- or YSK2-related coding sequence can be identified by any of at least four general approaches which are well-known in the art, including: (i) DNA-DNA, DNA-RNA, or RNA-antisense RNA hybridization; (ii) detecting the presence of "marker" gene functions; (iii) assessing the level of transcription as measured by the expression of MLK4-, PAK4-, PAK5- or YSK2-specific mRNA transcripts in the host cell; and
 5 (iv) detecting the presence of mature polypeptide product as measured, e.g., by immunoassay.

5.3.3. Expression And Characterization Of JNKKK Polypeptides

[0086] Once the MLK4-, PAK4-, PAK5- or YSK2-related coding sequence has been stably introduced into an appropriate host cell, the transformed host cell is clonally propagated, and the resulting cells are grown under conditions conducive to the maximum production of the MLK4-, PAK4-, PAK5- or YSK2-related gene products. Such conditions typically include growing cells to high density. Where the expression vector comprises an inducible promoter, appropriate induction conditions such as, e.g., temperature shift, exhaustion of nutrients, addition of gratuitous inducers (e.g., analogs of carbohydrates, such as isopropyl- β -D-thiogalactopyranoside (IPTG)), accumulation of excess metabolic
 15 by-products, or the like, are employed as needed to induce expression.

[0087] Where the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene product is retained inside the host cells, the cells are harvested and lysed, and the product is isolated and purified from the lysate under extraction conditions known in the art to minimize protein degradation such as, e.g., at 4°C, or in the presence of protease inhibitors, or both. Where the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene product is secreted from the host cells, the
 20 exhausted nutrient medium can simply be collected and the product isolated therefrom.

[0088] The expressed MLK4-, PAK4-, PAK5- or YSK2-related gene product can be isolated or substantially purified from cell lysates or culture medium, as appropriate, using standard methods, including but not limited to any combination of the following methods: ammonium sulfate precipitation, size fractionation, ion exchange chromatography, HPLC, density centrifugation, and affinity chromatography. Where the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene products exhibit biological activity, increasing purity of the preparation can be monitored at each step of the purification procedure by use of an appropriate assay. Whether or not the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene products exhibit biological activity, each can be detected as based, e.g., on size, or reactivity with an antibody otherwise specific for MLK4, PAK4, PAK5 or YSK2, or by the presence of a fusion tag.

[0089] The present invention thus provides a substantially purified or isolated polypeptide encoded by a polynucleotide molecule of the present invention. In a specific though non-limiting embodiment, the polypeptide is a human MLK4 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:2. In another specific though non-limiting embodiment, the polypeptide is a human PAK4 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:4. In still another specific though non-limiting embodiment, the polypeptide is a human PAK5 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:6, 8 or 10. In another specific though non-limiting embodiment, the polypeptide is a human YSK-2 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:13. The present invention further provides substantially purified or isolated polypeptides that are homologous to any of the MLK4, PAK4, PAK5 or YSK2 gene products of the present invention, as homologous polypeptides are defined above. The present invention further provides peptide fragments of the MLK4, PAK4, PAK5 or YSK2 gene products or homologous polypeptides of the present invention, as peptide fragments are
 40 defined above. The substantially purified or isolated polypeptides of the present invention are useful for a variety of purposes, such as, e.g., screening for compounds that interact with MLK4, PAK4, PAK5 or YSK2 proteins, and hence are candidates for compounds that affect MLK4, PAK4, PAK5 or YSK2 activity (including the events involved in signal transduction), and for raising antibodies directed against MLK4, PAK4, PAK5 or YSK2 gene product. Such compounds and antibodies can be used in therapeutic methods to treat or prevent UV damage to the skin.

[0090] As used herein, a polypeptide is "substantially purified" where the polypeptide constitutes the majority (i.e., at least about 50%) by weight of the material in a particular preparation. Also, as used herein, a polypeptide is "isolated" where the polypeptide constitutes at least about 90 wt% of the material in a particular preparation. Also, as used herein, a polynucleotide molecule is "isolated" where it constitutes at least about 90 wt% of the nucleic acid material in a particular preparation, or where it appears to be separated from all other polynucleotide molecules as determined, e.g., by
 50 gel electrophoresis techniques.

[0091] The present invention further provides a method of preparing a substantially purified or isolated MLK4 gene product, PAK4 gene product, PAK5 gene product, YSK2 gene product or peptide fragment of the present invention, comprising culturing a host cell transformed or transfected with a polynucleotide molecule or recombinant vector of the present invention, said recombinant vector comprising a polynucleotide molecule comprising a nucleotide sequence encoding the MLK4 gene product, PAK4 gene product, PAK5 gene product, YSK2 gene product or peptide fragment,
 55 respectively, of the present invention, wherein the nucleotide sequence is in operative association with one or more regulatory elements, under conditions conducive to the expression of the particular gene product, polypeptide, or peptide fragment, and recovering the expressed gene product, polypeptide, or peptide fragment, from the cell culture in a sub-

stantially purified or isolated form.

[0092] Once an MLK4, PAK4, PAK5 or YSK2 gene product of sufficient purity has been obtained, it can be characterized by standard methods, including by SDS-PAGE, size exclusion chromatography, amino acid sequence analysis, biological activity such as kinase activity, etc. For example, the amino acid sequence of the MLK4, PAK4, PAK5 or YSK2 gene product can be determined using standard peptide sequencing techniques. The MLK4, PAK4, PAK5 or YSK2 gene product can be further characterized using hydrophilicity analysis (see, e.g., Hopp and Woods, 1981, Proc. Natl. Acad. Sci. USA 78:3824), or analogous software algorithms, to identify hydrophobic and hydrophilic regions of the MLK4, PAK4, PAK5 or YSK2 gene product respectively. Structural analysis can be carried out to identify regions of the MLK4, PAK4, PAK5 or YSK2 gene product that assume specific secondary structures. Biophysical methods such as X-ray crystallography (Engstrom, 1974, Biochem. Exp. Biol. 11:7-13), computer modeling (Eletterick and Zoller (eds), 1986, in: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), and nuclear magnetic resonance (NMR) can be used to map and study sites of interaction between the MLK4, PAK4, PAK5 or YSK2 gene products and their substrates. Information obtained from these studies can be used to select specific sites on the MLK4, PAK4, PAK5 or YSK2 gene products as potential targets for drug candidates that interact with, and alter the activity of, these gene products.

5.4. Antibodies

[0093] The present invention further provides polyclonal and monoclonal antibodies that bind to an MLK4 gene product, PAK4 gene product, PAK5 gene product, YSK2 gene product, or to an homologous polypeptide or peptide fragment, of the present invention. Such antibodies can be used as affinity reagents with which to purify a native MLK4, PAK4, PAK5 or YSK2 gene product, or to analyze the activity or biological function of the MLK4, PAK4, PAK5 or YSK2 gene product.

[0094] Antibodies can be raised against any of the MLK4-, PAK4-, PAK5- or YSK2-related polypeptides of the present invention. Various host animals, including but not limited to cows, horses, rabbits, goats, sheep, and mice, can be used according to known methods to produce anti-MLK4, anti-PAK4, anti-PAK5 or anti-YSK2-specific antibodies. Various adjuvants known in the art can be used to enhance antibody production.

[0095] Polyclonal antibodies can be obtained from immunized animals and tested for anti-MLK4, anti-PAK4, anti-PAK5 or anti-YSK2 specificity using standard techniques. Alternatively, monoclonal antibodies to an MLK4, PAK4, PAK5 or YSK2 polypeptide can be prepared using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (Nature, 1975, 256: 495-497); the human B-cell hybridoma technique (Kosbor, et al., 1983, Immunology Today 4:72; Cote, et al., 1983, Proc. Natl. Acad. Sci. USA 80: 2026-2030); and the EBV-hybridoma technique (Cole, et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77- 96). Alternatively, techniques described for the production of single chain antibodies (see, e.g., U.S. Patent 4,946,778) can be adapted to produce MLK4-, PAK4-, PAK5- or YSK2- specific single chain antibodies. These publications are incorporated herein by reference.

[0096] Antibody fragments that contain specific binding sites for an MLK4, PAK4, PAK5 or YSK2 polypeptide are also encompassed within the present invention and can be generated by known techniques. Such fragments include but are not limited to F(ab')₂ fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries can be constructed (Huse *et al.*, 1989, Science 246: 1275-1281) to allow rapid identification of Fab fragments having the desired specificity to the MLK4, PAK4, PAK5 or YSK2 polypeptide.

[0097] Techniques for the production of monoclonal antibodies and antibody fragments are well-known in the art, and are additionally described, among other places, in Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory; and in J. W. Goding, 1986, Monoclonal Antibodies: Principles and Practice, Academic Press, London. All of the above-cited publications are incorporated herein by reference.

5.5. Anti-sense Oligonucleotides And Ribozymes

[0098] Also within the scope of the present invention are oligonucleotide sequences that include anti-sense oligonucleotides, phosphorothioates and ribozymes that function to bind to, degrade and/or inhibit the translation of MLK4, PAK4, PAK5 or YSK2 mRNA.

[0099] Anti-sense oligonucleotides, including anti-sense RNA molecules and anti-sense DNA molecules, act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. For example, antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the DNA sequence encoding an MLK4, PAK4, PAK5 or YSK2 polypeptide can be synthesized, e.g., by conventional phosphodiester techniques.

[0100] Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of MLK4, PAK4, PAK5 or YSK2 mRNA sequences are also within the scope of the present invention.

[0101] Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites that include the following sequences, GUA, GUU, and GUC. Once identified, short RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides using, e.g., ribonuclease protection assays.

[0102] Both the anti-sense oligonucleotides and ribozymes of the present invention can be prepared by known methods. These include techniques for chemical synthesis such as, e.g., by solid phase phosphoramidite chemical synthesis. Alternatively, anti-sense RNA molecules can be generated by in vitro or in vivo transcription of DNA sequences encoding the RNA molecule. Such DNA sequences can be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.

[0103] Various modifications to the oligonucleotides of the present invention can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2'-O-methyl rather than phosphodiesterase linkages within the oligonucleotide backbone.

5.6. Detection Of JNKKK Gene Products, And Diagnostic And Therapeutic Uses

[0104] The MLK4, PAK4, PAK5 and YSK2 polynucleotide molecules, oligonucleotides, and polypeptides of the present invention, as well as antibodies of the present invention that recognize the MLK4, PAK4, PAK5 or YSK2 polypeptides, are useful in the diagnosis of diseases or conditions resulting from alteration in the expression of MLK4, PAK4, PAK5 or YSK2 gene products. Alteration in expression can be either an increase or decrease in transcription of the MLK4, PAK4, PAK5 or YSK2 gene, or an increase or decrease in translation of an MLK4, PAK4, PAK5 or YSK2 gene product. Alternatively, the presence of mutations, alleles, or polymorphisms in the MLK4, PAK4, PAK5 or YSK2 gene sequence can be correlated with diseases or conditions, including but not limited to increased or decreased susceptibility to skin damage caused by ultraviolet light or other stresses, or psoriasis.

[0105] Nucleic acid-based detection methods are well known in the art and include hybridization assays (e.g., Northern and Southern hybridizations, nuclease protection), polymerase chain reaction (PCR) assays, and ligation chain reaction (LCR) assays, or combinations of the above (e.g., in situ hybridization). Such assays make use of the MLK4, PAK4, PAK5 or YSK2 polynucleotides and oligonucleotides of the present invention, including complementary sequences, as described above. If analysis of an RNA gene product is desired, certain assays would typically include a reverse transcription step prior to amplification and/or hybridization, as known in the art. Such nucleic acid based techniques can be designed by those of ordinary skill in the art to assay the levels of MLK4, PAK4, PAK5 or YSK2 gene expression, or the presence or absence of particular mutations, alleles or polymorphisms.

[0106] Protein or polypeptide-based detection methods are also well known to those of ordinary skill and include, e.g., immunological assays such as Western blot, immunoprecipitation of labeled target, and ELISA assays. These assays use the antibodies of the present invention described above. Again, such assays can measure levels of MLK4, PAK4, PAK5 or YSK2 polypeptides expressed by a cell or organism, or the presence of mutants, alleles, or polymorphisms in the MLK4, PAK4, PAK5 or YSK2 polypeptides.

[0107] If an abnormal condition is associated with the over- or under-production of an MLK4, PAK4, PAK5 or YSK2 gene product, the polynucleotides and oligonucleotides of the invention can be useful in preventing, ameliorating or otherwise treating the abnormal condition. For example, by introducing gene sequences into cells, gene therapy can be used to treat conditions in which the cells express inadequate levels of MLK4, PAK4, PAK5 or YSK2 gene product, or express abnormal or inactive MLK4, PAK4, PAK5 or YSK2 polypeptides. In some instances, abnormal conditions characterized by over-expression of MLK4, PAK4, PAK5 or YSK2 gene product can be prevented or treated using the gene therapy techniques described below. Specifically, gene therapy vectors can be designed to express anti-sense polynucleotides or ribozymes of the present invention as described above, thereby reducing the amount of MLK4, PAK4, PAK5 or YSK2 gene products that are effectively translated into polypeptide.

[0108] Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or papilloma virus can be used for delivery of recombinant MLK4, PAK4, PAK5 or YSK2 polynucleotides into the targeted cell population. Methods that are well known to those skilled in the art can be used to construct recombinant viral vectors containing an MLK4, PAK4, PAK5 or YSK2 polynucleotide. See, for example, the techniques described in Maniatis et al., 1989, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.; and

Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y. Alternatively, recombinant, non-viral vectors containing an MLK4, PAK4, PAK5 or YSK2 polynucleotide can be reconstituted into liposomes for delivery to target cells, or can be delivered as a naked polynucleotide, such as, e.g., in a "DNA Vaccine," to name just a few examples.

5.7. Drug Screening Applications

[0109] MLK4, PAK4, PAK5 and YSK2 gene products, including polynucleotides, oligonucleotides and polypeptides, can be used in screening assays to identify compounds that specifically bind to MLK4, PAK4, PAK5 or YSK2 gene products and thus have potential use as agonists or antagonists of MLK4, PAK4, PAK5 or YSK2 polypeptides, respectively. In a particular preferred use, the polynucleotides and polypeptides of the invention are useful to screen for compounds that affect the kinase activities of MLK4, PAK4, PAK5 or YSK2 polypeptides.

[0110] The invention thus provides assays to detect molecules that specifically bind to MLK4, PAK4, PAK5 or YSK2 polypeptides. For example, recombinant cells expressing an MLK4, PAK4, PAK5 or YSK2 polynucleotide can be used to recombinantly produce an MLK4, PAK4, PAK5 or YSK2 polypeptide, respectively, and to screen for molecules that bind to an MLK4, PAK4, PAK5 or YSK2 polypeptide, respectively. Methods that can be used to carry out the foregoing are commonly known in the art.

[0111] Diversity libraries, such as random or combinatorial peptide or non-peptide libraries can be screened for molecules that specifically bind to an MLK4, PAK4, PAK5 or YSK2 polypeptide. Many libraries are known in the art that can be used such as, e.g., chemically synthesized libraries, recombinant (e.g., phage display) libraries, and in vitro translation-based libraries.

[0112] Examples of chemically synthesized libraries are described in Fodor et al., 1991, Science 251:767-773; Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242, dated October 14, 1993; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

[0113] Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, R.B. et al., 1992, J. Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318, dated August 18, 1994.

[0114] In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058, dated April 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

[0115] In one example, non-peptide libraries, such as a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712), can be screened. Peptoid libraries, such as that described by Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371, can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

[0116] Screening the libraries can be accomplished by any of a variety of commonly known methods. See, for example, the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992, BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al., 1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and PCT Publication No. WO 94/18318.

[0117] In a specific embodiment, screening can be carried out by contacting the library members with an MLK4, PAK4, PAK5 or YSK2 polypeptide immobilized on a solid phase and harvesting those library members that bind to the polypeptide. Examples of such screening methods, termed "panning" techniques, are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in other references cited hereinabove.

[0118] In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to an MLK4, PAK4, PAK5 or YSK2 polypeptide within a cell.

[0119] In another aspect of the invention, methods for screening candidate compounds for drugs are provided. Such drugs can be used to reduce ultraviolet light-induced damage, inflammation and psoriasis, and enhance wound healing in a subject. The subject is an animal, typically a mammal, preferably a human.

[0120] For example, one can screen for compounds that affect the expression of an MLK4, PAK4, PAK5 or YSK2

gene product of the present invention by: (a) applying a test compound to a test sample; (b) determining the expression of at least one MLK4, PAK4, PAK5 or YSK2 gene product in the test sample; and (c) comparing the expression of the gene in the test sample with that in a reference sample. A specific change in the cellular level of the gene product in the test sample as compared to the reference sample indicates that the compound affects the cellular level of gene product from a JNKKK gene. By the term "a specific change in the cellular level of the gene product" is meant that the change in level occurs without alteration of overall transcription or translation levels in the cell (depending upon the gene product assayed). For example, when mRNA is measured, a compound that causes a "specific change" is not a compound that is a general transcriptional repressor. Similarly, for example, when protein levels are assayed, a compound that causes a "specific change" is not a general translational repressor. One can determine whether global effects on transcription or translation occur in the presence of a test compound by assaying for a control housekeeping gene product (e.g., glucose-6-phosphate dehydrogenase gene product or the actin gene product, to name just two examples).

[0121] One can also assay the effect of a test compound on the expression or cellular response of the MLK4, PAK4, PAK5 or YSK2 gene or polypeptide in the presence of, or in response to, a stress event. The stress event applied to the cells can be exposure to ultraviolet radiation. Preferred ultraviolet radiation can be UV-A with a wavelength in the range of 320-400 nm, or UV-B with a wavelength in the range of 280-320 nm, or UV-C with a wavelength in the range of 200-280 nm. Other types of stress events applied to the sample for screening purposes can be exposure to inflammatory cytokines such as TNF- α , IL-1, interferons, FGFs or PDGF. Still other types of stress events are heat shock, osmotic shock, exposure to toxic chemicals such as arsenic, disruption of the permeability barrier (e.g., with solvents), etc.

[0122] In one preferred embodiment, the method of drug screening comprises: (a) applying a test compound to a test sample; (b) exposing the test sample and a reference sample to a stress event; (c) determining the expression of at least one gene product in the test sample, wherein the transcript of the gene product comprises a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11 and 12; and (d) determining the effectiveness of the test compound in blocking or otherwise modulating the cellular response to the stress event by comparing the expression of the gene product in the test sample with that in the reference sample. If the test compound significantly reduces the expression of the transcript in response to the stress event, the test compound is identified as a drug candidate that may be potentially effective in blocking the cellular response to the stress event. The expression of the MLK4, PAK4, PAK5 or YSK2 gene product can be determined using any of the methods described above. The most preferred gene products for use in this assay are the PAK5 and YSK2 gene products.

[0123] In another preferred embodiment, the method of drug screening entails: (a) applying a test compound to a test sample; (b) applying a stress event to the test sample; and (c) determining the amount of an MLK4, PAK4, PAK5 or YSK2 polypeptide in the test sample and in a reference sample, wherein the MLK4, PAK4, PAK5 or YSK2 polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NOS: 2, 4, 6, 8, 10 and 13; wherein a reduction in the amount of the MLK4, PAK4, PAK5 or YSK2 polypeptide in the test sample as compared to that in the reference sample indicates that the test compound is identified as a drug candidate that can potentially block the stress response.

[0124] Still another aspect of the invention is a method of screening for compounds that affect the activity of an MLK4, PAK4, PAK5 or YSK2 polypeptide. One can apply a test compound to a test sample and determine the activity of the MLK4, PAK4, PAK5 or YSK2 polypeptide in the test sample compared to that in a reference sample. A test compound that alters the MLK4, PAK4, PAK5 or YSK2 polypeptide activity in the test sample as compared to the reference sample is identified as a drug candidate that can potentially affect the activity of the MLK4, PAK4, PAK5 or YSK2 polypeptide. Each of the full-length MLK4, PAK4, PAK5 and YSK2 polypeptides is a kinase; thus, the activities of these polypeptides include kinase activity and binding to ATP and its analogs. Other activities include the ability to interact with activators that activate MLK4, PAK4, PAK5 or YSK2 polypeptide kinase activity, interaction with downstream target proteins, and interaction with inhibitors via the amino-terminal regulatory domain:

[0125] In another preferred embodiment, the activity of MLK4, PAK4, PAK5 or YSK2 polypeptides, such as kinase activity, binding to ATP and its analogs, or activation of downstream target protein, can be assayed in the test and reference samples in response to application of a stress event, and compared, to predict the effectiveness of the drug candidate. If the drug candidate prevents the induction of the function of the MLK4, PAK4, PAK5 or YSK2 polypeptide by a particular stress event, such as ultraviolet radiation, the drug candidate can be effective at blocking the stress response.

[0126] In some preferred embodiments, the test and reference samples are cultured cells, tissues or organs. In other preferred embodiments, the test and reference samples are live animals. In a particularly preferred embodiment, a small biopsy of human skin (e.g., about 5 mm³) is placed in culture and treated with, e.g., ultraviolet radiation, one or more growth factors, cytokines, drugs, hormones or vitamins. After a defined period of time (typically 24-48 hours when the treatment is ultraviolet radiation), the biopsy is tested for expression of the MLK4, PAK4, PAK5 or YSK2 gene product, or for activity of the MLK4, PAK4, PAK5 or YSK2 polypeptide.

[0127] The invention having been described, the following examples are offered by way of illustration and not limitation.

6. Example: Cloning Of The YSK2, MLK4, PAK4 And PAK5 cDNAs

[0128] This example illustrates the methods used to clone the novel JNKKKs of the invention.

6.1. Materials And Methods

[0129] Normal human foreskin epidermal keratinocytes were a generous gift from Dr. M. Simon of the State University of New York at Stony Brook. The cultures were initiated using 3T3 feeder layers and then frozen in liquid nitrogen until used. Once thawed, the keratinocytes were grown without feeder cells in defined serum-free keratinocyte growth medium (KGM), supplemented with bovine pituitary extract epidermal growth factor, insulin, thyroid hormone and hydrocortisone (keratinocyte-SFM, GIBCO).

[0130] Messenger RNA from the keratinocytes was used for reverse transcription polymerase chain reaction (RT-PCR) amplification with an RT-PCR kit (Promega Corp., Madison, Wisconsin). Primers corresponding to regions of homology between the kinase domains of JNKKs or JNKKKs were designed to amplify a 150 bp PCR products from keratinocyte mRNA using RT-PCR. The primers contain the following sequences that correspond to the regions of the kinase domain.

Forward: 5'-ATGCA(CA)CANGA(CT)AT(ACT)AA(AG)-3' (SEQ ID NO: 14)

Reverse: 5'-GCNAC(CT)TCNGGNGCCATCCA-3' (SEQ ID NO: 15)

[0131] The actual primers used for RT-PCR also contained cloning sites. Their sequences are as follows:

Forward: 5'-CCCGAATTCATGCA(CA)CANGA(CT)AT(ACT)AA(AG)-3' (SEQ ID NO:16)

Reverse: 5'-CCCGAATTCGCNAC(CT)TCNGGNGCCATCCA-3' (SEQ ID NO: 17)

[0132] The PCR products were sub-cloned and sequenced.

6.2. Results

[0133] Among the seventy different clones sequenced, ten different JNKKKs were identified, four of which appeared to be novel. An amino acid sequence comparison against the protein databases in the European Molecular Biology Network (available at HYPERLINK <http://www.expasy.ch>; <http://www.expasy.ch>; <http://www.ch.embnnet.org>) with other JNKKKs revealed that the four novel JNKKKs exhibited some degree of homology to various known JNKKKs from several different families. One JNKKK clone was 91% identical at positions 12-131 to a 134 base region of the murine YSK2 gene sequence (corresponding to positions 503-384 of emb: U49949, Osada et al., 1997, Oncogene 14:2047-2057); hence, this clone was designated as the human keratinocyte YSK2 (SEQ ID NO:12). Additionally, two human expressed sequence tags (ESTs) were related to the human keratinocyte YSK2. Specifically, Human EST emb:AA557573 (NCI-CGAP, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index <http://www.ncbi.nlm.nih.gov/ncicgap>," Unpublished.) showed a 96% identity with the human YSK2 gene sequence (SEQ ID NO:12) in a 137 bp region corresponding to positions 6-142 of SEQ ID NO:12 and positions 32-168 of emb:AA557573. Human EST emb:AA578088 (NCI-CGAP, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index <http://www.ncbi.nlm.nih.gov/ncicgap>," Unpublished.) also showed a 96% identity with the SEQ ID NO:12 in a 136 bp region corresponding to positions 6-141 of SEQ ID NO:12 and positions 35-170 of emb:AA578088.

[0134] Another JNKKK clone, designated MLK4 (SEQ ID NO:1), was 50% to 78% identical to members of the MLK family of JNKKKs. Finally, two JNKKK clones, designated PAK4 (SEQ ID NO:3) and PAK5 (SEQ ID NO:5), showed similar identity to members of the PAK family of JNKKKs. However, no homolog sequences could be found in the European Molecular Biology Network protein database for either MLK4 or PAK5. Although initial sequence searches of PAK4 indicated it was a new member of the PAK gene family, during the course of this work, the complete sequence of human PAK4 was published (Abo et al., 1998, EMBO J 22:6527-6540).

[0135] The relative abundance of the different identified JNKKKs is shown below in TABLE 1 below.

Table 1

ABUNDANCE OF DIFFERENT JNKKKs	
Kinase	Number of Isolates
BPAG1*	1
GCK	3
LIMK	1
MEKK3	4
MLK4	2
NiK	94
PAK1	40
PAK2	31
PAK4	69
PAK5	59
YSK1	1
Ysk2	51
Total	356

*LIMK is a protein kinase, related to, but not a member of, the JNKKK family. Frangiskakis et al., 1996, Cell 86:59-69. BPAG1 is an abundant protein in basal keratinocytes. Its mRNA contains two segments recognized by the 8 bases at the 3' termini of our oligonucleotides.

[0136] The RT-PCR products (SEQ ID NOS:1, 3, 5, 12) of the MLK4, PAK4, PAK5 and YSK2 mRNAs were used as probes for Northern Hybridization to mRNAs from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Figure 2 shows that the expression of the PAK4 gene is ubiquitous among the organs tested. However, the PAK5 gene is strongly expressed in keratinocytes and in the brain, but not expressed, or only weakly expressed, in placenta, lung, liver, skeletal muscle, kidney and pancreas. The MLK4 gene is expressed in keratinocytes, kidney and pancreas, but not in the brain, placenta, lung, liver, and skeletal muscle. The size of the transcripts of PAK4, PAK5 and MLK4 are 3.4, 4.4 and 4.8 kb, respectively.

7. Example: Genomic Sequence Of The PAK5 Gene

[0137] Oligonucleotides 5'-GAGTGACTCCATCCTGC-3' (SEQ ID NO: 18) and 5'-GTAGGGGGTTCCCACCA-3' (SEQ ID NO: 19) were used to identify a genomic clone from a commercially available P1 human library (Genome Systems, Inc., St. Louis, MO) that contained the PAK5 gene. The P1 genomic clone was partially sequenced, and additional coding sequence deduced. The polynucleotide sequence, with deduced exons indicated, is presented as SEQ ID NO:7. SEQ ID NO:8 presents the deduced amino acid sequence from the partial genomic sequence. A partial schematic structure of the PAK5 gene is depicted in Figure 1. A PLC-2 gene was found to be linked to the PAK5 gene in the P1 clone. The PLC-2 gene has been mapped to chromosome 15; thus, the PAK5 gene also must reside on chromosome 15.

[0138] The deduced amino acid sequence of the PAK5 protein (SEQ ID NO:8) is very similar to that of PAK4 (SEQ ID NO:4), especially in the kinase domain (amino acid residues 93 to 311 in SEQ ID NO:8). The kinase domains of any of the JNKKKs of the present invention have utility as enzymatically active domains to phosphorylate substrates. The sequence of the PAK5 kinase domain contains a conserved lysine (K) residue that is essential for ATP binding (amino

acid residue 120 in SEQ ID NO:8). By analogy with PAK4, mutations that change this lysine residue in PAK5 to alanine or methionine residues will abolish PAK5 enzymatic activity, while mutations that change the lysine residue to a glutamine will make a full length PAK5 protein constitutively active. Less homology between PAK4 and PAK5 is observed outside of the kinase domain. The 21 residue carboxy terminal extension of PAK5 is 4 amino acids longer than that of PAK4. Additionally, the available amino terminal sequences of the PAK5 protein bear no similarity to any known protein other than PAK4. Thus, both the carboxy terminal and the amino terminal regions of the PAK5 protein will be particularly useful in generating antibodies that immunospecifically recognize PAK5.

[0139] The ORF of the complete human cDNA sequence of PAK5 is presented in SEQ ID NO:9 from nt 199-2244. The complete DNA sequence for the human PAK5 gene is presented in SEQ ID NO:10, with the ORF from nt 6125-17433.

8. Example: Ultraviolet Radiation-Induced Expression Of YSK2 And PAK5 mRNA

[0140] In this example, the effect of various wavelengths of ultraviolet radiation on the expression of the novel JNKs was investigated. The effects of both UV-C light (short wavelength ultraviolet radiation of 220 to 290 nm) and UV-A light (long wavelength ultraviolet radiation of 320 to 400 nm) were separately analyzed.

[0141] Keratinocytes were grown as described in Section 6.1, above. The cells were expanded through two 1:4 passages before illumination with 3-10 mJ/cm² of UV-C light or 1-5 J/cm² of UV-A light. Cells were harvested 6 or 24 hours after exposure. PolyA mRNA was purified from the cells using kits from Qiagen.

[0142] Figure 3A shows that the YSK2 gene is induced by UV-C light. Keratinocytes were exposed to 10 mJ/cm² of UV-C light. Messenger RNAs from control and UV-C light-treated cells were separated by electrophoresis and transferred to a membrane by Northern blotting. The membrane was then hybridized using the 190 bp YSK2 RT-PCR product labeled with ³²P-dNTPs as the probe. As Figure 3A shows, the expression of the YSK2 gene in keratinocytes was greatly enhanced by UV-C light exposure.

[0143] Figure 3B shows that the PAK5 gene is induced by UV-A light treatment. Human keratinocytes were exposed to UV-A light (5 mJ/cm²), harvested, and mRNA prepared from the cells. The levels of PAK4 and PAK5 mRNA in treated and untreated cells were compared using differential display. Liang and Pardee, 1992, Science 257:967-71. Amplification was performed using primer SEQ ID NOS:14 and 15, or SEQ ID NO:16 and 17, above. The resulting amplified DNA was then digested with restriction enzyme TaqI to reveal specifically the PAK4 and the PAK5 DNAs. The results demonstrate that PAK5 is induced by ultraviolet radiation.

[0144] Differential display experiments (Figures 3A and 3B) show that expression of both YSK2 and PAK5 genes are induced by ultraviolet radiation. However, induction of the two genes is dependent upon the wavelength of the ultraviolet radiation. YSK2 gene expression is induced by UV-C, which is the short wavelength ultraviolet radiation (220 to 290 nm). In contrast, the PAK5 gene expression is induced by UV-A, which is the long wavelength ultraviolet radiation (320 to 400 nm). The induction of YSK2 and PAK5 gene expression by ultraviolet radiation suggests that the products of the two genes are involved in the signal transduction cascade that transduces extracellular ultraviolet radiation (or other stress signals). Although MLK4 and PAK4 mRNA gene expression were not induced by ultraviolet radiation in these experiments, this fact cannot rule out a role in the keratinocyte response to light or other stresses. These gene products can be involved in the early cellular events in response to stress prior to any changes in gene expression.

[0145] The foregoing written specification is sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above-described means for carrying out the invention which are obvious to those skilled in the field of molecular biology, medicine or related fields are intended to be within the scope of the following claims.

[0146] All references referred to herein above are incorporated herein by reference in their entirety.

SEQUENCE LISTING

5 <110> New York University
 <120> GENES AND POLYNUCLEOTIDES ASSOCIATED WITH ULTRAVIOLET
 RADIATION-MEDIATED SKIN DAMAGE AND USES THEREOF
 10 <130> PC10489A
 <140>
 <141>
 15 <150> 60/155,029
 <151> 1999-09-20
 <160> 19
 20 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 164
 <212> DNA
 25 <213> Homo sapiens
 <220>
 <221> CDS
 30 <222> (2)..(163)
 <400> 1
 g cac cgg gac atc aag gca gga aat att ttg cta ctt gag aag ata gaa 49
 His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Leu Glu Lys Ile Glu
 35 1 5 10 15
 cat gat gac atc tgc aat aaa act ttg aag att aca gat ttt ggg ttg 97
 His Asp Asp Ile Cys Asn Lys Thr Leu Lys Ile Thr Asp Phe Gly Leu
 20 25 30
 40 gcg agg gaa tgg cac agg acc acc aaa atg agc aca gca ggc acc tat 145
 Ala Arg Glu Trp His Arg Thr Thr Lys Met Ser Thr Ala Gly Thr Tyr
 35 40 45
 45 gcc tgg atg gcc cca gaa g 164
 Ala Trp Met Ala Pro Glu
 50
 50 <210> 2
 <211> 54
 55

EP 1 085 093 A2

<212> PRT

<213> Homo sapiens

<400> 2

His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Leu Glu Lys Ile Glu
1 5 10 15

His Asp Asp Ile Cys Asn Lys Thr Leu Lys Ile Thr Asp Phe Gly Leu
20 25 30

Ala Arg Glu Trp His Arg Thr Thr Lys Met Ser Thr Ala Gly Thr Tyr
35 40 45

Ala Trp Met Ala Pro Glu
50

<210> 3

<211> 145

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (2)..(145)

<400> 3

a cat cgg gac atc aag agc gac tcg atc ctg ctg acc cat gat ggc agg 49
His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr His Asp Gly Arg
1 5 10 15

gtg aag ctg tca gac ttt ggg ttc tgc gcc cag gtg agc aag gaa gtg 97
Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Val Ser Lys Glu Val
20 25 30

ccc cga agg aag tcg ctg gtc ggc acg ccc tac tgg atg gcc cca gag 145
Pro Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu
35 40 45

<210> 4

<211> 48

<212> PRT

<213> Homo sapiens

<400> 4

His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr His Asp Gly Arg

EP 1 085 093 A2

1 5 10 15

5 Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Val Ser Lys Glu Val
20 25 30

10 Pro Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu
35 40 45

15 <210> 5
<211> 146
<212> DNA
<213> Homo sapiens

20 <220>
<221> CDS
<222> (2)..(145)

25 <400> 5
t cac agg gac atc aag agt gac tcc atc ctg ctg acc ctc gat ggc agg 49
His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg
1 5 10 15

30 gtg aag ctc tcg gac ttc gga ttc tgt gct cag atc agc aaa gac gtc 97
Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val
20 25 30

35 cct aag agg aag tcc ctg gtg gga acc ccc tac tgg atg gcg ccc gag g 146
Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu
35 40 45

40 <210> 6
<211> 48
<212> PRT
<213> Homo sapiens

45 <400> 6
His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg
1 5 10 15

50 Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val
20 25 30

55 Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu
35 40 45

EP 1 085 093 A2

<210> 7
 <211> 3627
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> CDS
 <222> (868) .. (1275)

 <220>
 <221> CDS
 <222> (1420) .. (1553)

 <220>
 <221> CDS
 <222> (1900) .. (2026)

 <220>
 <221> CDS
 <222> (2105) .. (2230)

 <220>
 <221> CDS
 <222> (2696) .. (2833)

 <400> 7
 gatctgcgac ctccttcaga acctgccaaa atgactagga aaaatgctgt ttccatagca 60
 agagccaaaa gagaacatga cggccctgca ctccgggatc tctctggcac cagattccca 120
 gccagggga gacacctgaa cccccagat ggtgacacac ctctgtggtc ctctgtcagg 180
 gacataacct ccagcacag atttgcaaac tcctgctgc aggcacaagc agggctatcg 240
 ggccccaggt gtggctcccc tgccttggtt caggagtg agacacagtt gccactgct 300
 cccacccca ctgccaggcc tcttctgccc ccattgggtcc tggggtggg gagccttggg 360
 agttgaagaa tgcctctgac ccagattctt caagcagcct ctgagctcag aggaagagtc 420
 tgcctcacgg cagcctccct ggggtctagc tgtcaatcgc ccaggaagaa ataccagcg 480
 cgggaccgg cggggaagct ggccttctct gtcttcccag gtgcagcaca gcgagtgtaa 540
 ggagctgtct tgggcctgcc cagcctggtg ccctgcggg gactgctggc acaggactgt 600

EP 1 085 093 A2

gactgggctt cagctctgtc tgaaaatctt tgcttcagag cacctcccta gtttgatctg 660
 5 ataccccgcc tgacctgcc agagtccaga ggtcacggcg gccagcccct gcctccggga 720
 aggttattec aaatgctccc acagccctga cccttcctgt tgctttgtcc cttgcagccc 780
 aactcctctt tccgaccgcc gcagaaagac aaccccccaa gcctgggtggc caaggcccag 840
 10 tcttgccct cggaccagcc ggtgggg acc ttc agc cct ctg acc act tcg gat 894
 Thr Phe Ser Pro Leu Thr Thr Ser Asp
 1 5
 15 acc agc agc ccc cag aag tcc ctc cgc aca gcc ccg gcc aca ggc cag 942
 Thr Ser Ser Pro Gln Lys Ser Leu Arg Thr Ala Pro Ala Thr Gly Gln
 10 15 20 25
 20 ctt cca ggc cgg tct tcc cca gcg gga tcc ccc cgc acc tgg cac gcc 990
 Leu Pro Gly Arg Ser Ser Pro Ala Gly Ser Pro Arg Thr Trp His Ala
 30 35 40
 25 cag atc agc acc agc aac ctg tac ctg ccc cag gac ccc acg gtt gcc 1038
 Gln Ile Ser Thr Ser Asn Leu Tyr Leu Pro Gln Asp Pro Thr Val Ala
 45 50 55
 30 aag ggt gcc ctg gct ggt gag gac aca ggt gtt gtg aca cat gag cag 1086
 Lys Gly Ala Leu Ala Gly Glu Asp Thr Gly Val Val Thr His Glu Gln
 60 65 70
 35 ttc aag gct gcg ctc agg atg gtg gtg gac cag ggt gac ccc cgg ctg 1134
 Phe Lys Ala Ala Leu Arg Met Val Val Asp Gln Gly Asp Pro Arg Leu
 75 80 85
 40 ctg ctg gac agc tac gtg aag att ggc gag ggc tcc acc ggc atc gtc 1182
 Leu Leu Asp Ser Tyr Val Lys Ile Gly Glu Gly Ser Thr Gly Ile Val
 90 95 100 105
 45 tgc ttg gcc cgg gaa gaa cac tcg ggc cgc cag gtg gcc gtc aag atg 1230
 Cys Leu Ala Arg Glu Glu His Ser Gly Arg Gln Val Ala Val Lys Met
 110 115 120
 50 atg gac ctc aga aag cag cag cgc agg gag ctg ctc ttc aac gag 1275
 Met Asp Leu Arg Lys Gln Gln Arg Arg Glu Leu Leu Phe Asn Glu
 125 130 135
 55 gtgggaggac aggggtgggac acacacgggg gcgttgggga tgggcagtga gcagccagcc 1335
 aggctggaca tctgtgagca ggggcagtgg gtggccatgc gtctgggcac tgtgcctggc 1395

EP 1 085 093 A2

actcaggccc ccacctgccc ccag gtg gtg atc atg cgg gac tac cag cac 1446
Val Val Ile Met Arg Asp Tyr Gln His
140 145

5 ttc aac gtg gtg gag atg tac aag agc tac ctg gtg ggc gag gag ctg 1494
Phe Asn Val Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu Glu Leu
150 155 160

10 tgg gtg ctc atg gag ttc ctg cag gga gga gcc ctc aca gac atc gtc 1542
Trp Val Leu Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp Ile Val
165 170 175

15 tcc caa gtc ag gtgggcagct gggagggctg gaccctgagt gcaggctgcc 1593
Ser Gln Val Arg
180

20 ctcaccatgg ccctgccagg gcaatgtggt cttctgcctg tggcccagaa gacttgggat 1653
gcctgggctc ccctgcctgc tggggtaact gagaccaggg ggtcttggga gtggagaaga 1713
gaaggatagc ttctagccaa agctcaggcc ccagttttca ccagggtat ggctgactg 1773

25 tgctgcaaaa cagattgcct gggagctgtg gggcctagca ccagggaact ctactctgct 1833
cagccacccc acgacctgcc agagctaacg ttctctttca tcgggtggcc ccaccttcc 1893

30 gtccag g ctg aat gag gag cag att gcc act gtg tgt gag gct gtg ctg 1942
Leu Asn Glu Glu Gln Ile Ala Thr Val Cys Glu Ala Val Leu
185 190 195

35 cag gcc ctg gcc tac ctg cat gct cag ggt gtc atc cac cgg gac atc 1990
Gln Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile His Arg Asp Ile
200 205 210

40 aag agt gac tcc atc ctg ctg acc ctc gat ggc agg gtaggtccca 2036
Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg
215 220

tctgtccct ggcacagcca cgctcccaact tctcctgat ccaccactca ctccctttc 2096

45 aaccgcag gtg aag ctc tcg gac ttc gga ttc tgt gct cag atc agc aaa 2146
Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys
225 230 235

50 gac gtc cct aag agg aag tcc ctg gtg gga acc ccc tac tgg atg gct 2194
Asp Val Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala
240 245 250

55

EP 1 085 093 A2

cct gaa gtg atc tcc agg tct ttg tat gcc act gag gtaaccgttc 2240
 Pro Glu Val Ile Ser Arg Ser Leu Tyr Ala Thr Glu
 255 260 265
 5
 cctccacccc ccagacctcc caaaagcaac tgggcaactg gcagctcttc tgctgtggcc 2300
 cctccagtga gctcaccaaa agcagccctg gttttcagag tcccacctag tcaacaccct 2360
 10
 tccccctttc gatggggctg ctcttaccca gtgactttgc tgccagggaac gagtcctgca 2420
 agtgctttcc tcagctcaag ggcagaatgg ggtatggccg ggcctcctat gtatgatggc 2480
 15
 ctttctctga gtgactgaca gctgtgtccc tataggcagt ggtcactcat gcaggcagta 2540
 actggccaca gggcagggtga ccaggggagg aaggagacag acccaccaag gagagctggg 2600
 gccagctgtc cccctccac cactgctgcc accagaacgc agctaccaat gggccagggt 2660
 20
 ctggccatgg ggtcagggaac attttcctcc tgcag gtg gat atc tgg tct ctg 2713
 Val Asp Ile Trp Ser Leu
 270
 25
 ggg atc atg gtg att gag atg gta gat ggg gag cca ccg tac ttc agt 2761
 Gly Ile Met Val Ile Glu Met Val Asp Gly Glu Pro Pro Tyr Phe Ser
 275 280 285
 30
 gac tcc cca gtg caa gcc atg aag agg ctc cgg gac agc ccc cca ccc 2809
 Asp Ser Pro Val Gln Ala Met Lys Arg Leu Arg Asp Ser Pro Pro Pro
 290 295 300
 35
 aag ctg aaa aac tct cac aag gtc agttggcaca caagggtgag acctcgaga 2863
 Lys Leu Lys Asn Ser His Lys Val
 305 310
 40
 ccccatctct cctgaggcaa ggggaccaga acctgggctc ccagcatctc ccttccactg 2923
 aagccacagg gtctgggctc ctggaaaagg ctctctttc cccacacaaa acccgcacct 2983
 ggggtgtggag ccgcatctac gcacaagtgc gcatgtgagc tccgacaagt cgctccccc 3043
 45
 ggctgtggca ggagagttgc tgcttggcag aagggttgct gcttggcagg cactggtcgg 3103
 aagcccagtg gggcccatga gcagggaag ccaggacacc agcaactccc tgctgtccag 3163
 50
 ggaggggatcc ggagaagctt cactgagcac aaaccttca acccgtgtcg ggagatccat 3223
 accatgattc gatgtccctg tccatcacgg cgagtcggct catgtccat tcgttgacac 3283
 55

EP 1 085 093 A2

ccccgacaca gctaagccac agcgttcccc ttaaagccag tataagtgc tggaaagtgg 3343
 5 atacatgtaa ccctttttgc caaatcggcc ccaaccccg aggccttact gtggacgccc 3403
 cctgctggca ggtcagcacg gggctgataa gtggcaccgc catctggtgg ccaaaacaag 3463
 aaatgtctca gagggctgaa gcctctctc taaaatagca aaaaaacaag agttctgtgg 3523
 10 ccccaacaca aagctggatg ggaggaccaa caggaaacat ctccaagac aactggtcct 3583
 tggagcccg accgctaacc caaaattag catataaagc atgc 3627

<210> 8
 <211> 311
 <212> PRT
 <213> Homo sapiens

<400> 8
 Thr Phe Ser Pro Leu Thr Thr Ser Asp Thr Ser Ser Pro Gln Lys Ser
 1 5 10 15
 25 Leu Arg Thr Ala Pro Ala Thr Gly Gln Leu Pro Gly Arg Ser Ser Pro
 20 25 30
 Ala Gly Ser Pro Arg Thr Trp His Ala Gln Ile Ser Thr Ser Asn Leu
 35 40 45
 Tyr Leu Pro Gln Asp Pro Thr Val Ala Lys Gly Ala Leu Ala Gly Glu
 50 55 60
 35 Asp Thr Gly Val Val Thr His Glu Gln Phe Lys Ala Ala Leu Arg Met
 65 70 75 80
 Val Val Asp Gln Gly Asp Pro Arg Leu Leu Leu Asp Ser Tyr Val Lys
 85 90 95
 40 Ile Gly Glu Gly Ser Thr Gly Ile Val Cys Leu Ala Arg Glu Glu His
 100 105 110
 45 Ser Gly Arg Gln Val Ala Val Lys Met Met Asp Leu Arg Lys Gln Gln
 115 120 125
 Arg Arg Glu Leu Leu Phe Asn Glu Val Val Ile Met Arg Asp Tyr Gln
 130 135 140
 50 His Phe Asn Val Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu Glu
 145 150 155 160

EP 1 085 093 A2

Leu Trp Val Leu Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp Ile
165 170 175

5 Val Ser Gln Val Arg Leu Asn Glu Glu Gln Ile Ala Thr Val Cys Glu
180 185 190

Ala Val Leu Gln Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile His
10 195 200 205

Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg Val
210 215 220

15 Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val Pro
225 230 235 240

Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu Val
20 245 250 255

Ile Ser Arg Ser Leu Tyr Ala Thr Glu Val Asp Ile Trp Ser Leu Gly
260 265 270

25 Ile Met Val Ile Glu Met Val Asp Gly Glu Pro Pro Tyr Phe Ser Asp
275 280 285

Ser Pro Val Gln Ala Met Lys Arg Leu Arg Asp Ser Pro Pro Pro Lys
30 290 295 300

Leu Lys Asn Ser His Lys Val
305 310

35

<210> 9
<211> 2669
<212> DNA
40 <213> Homo sapiens

<220>
<221> CDS
45 <222> (199)..(2244)

<400> 9
gagtgccgct tcctgggcta gagacaagca ccagcctgca gtggagaacg caggaccccg 60
50 ctgcccagaa ggagcagcca cggcctgcgg aggactggcc cagcaaggtc ccaggtcttc 120
cctctctca gcgcctaaga gagagygcca gtgcgggtga ggagtcgca ggaagaggcg 180

EP 1 085 093 A2

gaaggcgccg gaaggacc atg ttc cgc aag aaa aag aag aaa cgc cct gag 231
Met Phe Arg Lys Lys Lys Lys Lys Arg Pro Glu
1 5 10

atc tca gcg cca cag aac ttc cag cac cgt gtc cac acc tcc ttc gac 279
Ile Ser Ala Pro Gln Asn Phe Gln His Arg Val His Thr Ser Phe Asp
15 20 25

ccc aaa gaa ggc aag ttt gtg ggc ctc ccc cca caa tgg cag aac atc 327
Pro Lys Glu Gly Lys Phe Val Gly Leu Pro Pro Gln Trp Gln Asn Ile
30 35 40

ctg gac aca ctg cgg cgc ccc aag ccc gtg gtg gac cct tcg cga atc 375
Leu Asp Thr Leu Arg Arg Pro Lys Pro Val Val Asp Pro Ser Arg Ile
45 50 55

aca cgg gtg cag ctc cag ccc atg aag aca gtg gtg cgg ggc agc gcg 423
Thr Arg Val Gln Leu Gln Pro Met Lys Thr Val Val Arg Gly Ser Ala
60 65 70 75

atg cct gtg gat ggc tac atc tcg ggg ctg ctc aac gac atc cag aag 471
Met Pro Val Asp Gly Tyr Ile Ser Gly Leu Leu Asn Asp Ile Gln Lys
80 85 90

ttg tca gtc atc agc tcc aac acc ctg cgt ggt cgc agc ccc acc agc 519
Leu Ser Val Ile Ser Ser Asn Thr Leu Arg Gly Arg Ser Pro Thr Ser
95 100 105

cgg cgg cgg gca cag tcc ctg ggg ctg ctg ggg gat gag cac tgg gcc 567
Arg Arg Arg Ala Gln Ser Leu Gly Leu Leu Gly Asp Glu His Trp Ala
110 115 120

acc gac cca gac atg tac ctc cag agc ccc cag tct gag cgc act gac 615
Thr Asp Pro Asp Met Tyr Leu Gln Ser Pro Gln Ser Glu Arg Thr Asp
125 130 135

ccc cac ggc ctc tac ctc agc tgc aac ggg ggc aca cca gca ggc cac 663
Pro His Gly Leu Tyr Leu Ser Cys Asn Gly Gly Thr Pro Ala Gly His
140 145 150 155

aag cag atg ccg tgg ccc gag cca cag agc cca cgg gtc ctg ccc aat 711
Lys Gln Met Pro Trp Pro Glu Pro Gln Ser Pro Arg Val Leu Pro Asn
160 165 170

ggg ctg gct gca aag gca cag tcc ctg ggc ccc gcc gag ttt cag ggt 759
Gly Leu Ala Ala Lys Ala Gln Ser Leu Gly Pro Ala Glu Phe Gln Gly
175 180 185

EP 1 085 093 A2

5 gcc tcg cag cgc tgt ctg cag ctg ggt gcc tgc ctg cag agc tcc cca 807
 Ala Ser Gln Arg Cys Leu Gln Leu Gly Ala Cys Leu Gln Ser Ser Pro
 190 195 200

10 cca gga gcc tcg ccc ccc acg ggc acc aat agg cat gga atg aag gct 855
 Pro Gly Ala Ser Pro Pro Thr Gly Thr Asn Arg His Gly Met Lys Ala
 205 210 215

15 gcc aag cat ggc tct gag gag gcc cgg cca cag tcc tgc ctg gtg ggc 903
 Ala Lys His Gly Ser Glu Glu Ala Arg Pro Gln Ser Cys Leu Val Gly
 220 225 230 235

20 tca gcc aca ggc agg cca ggt ggg gaa ggc agc cct agc cct aag acc 951
 Ser Ala Thr Gly Arg Pro Gly Gly Glu Gly Ser Pro Ser Pro Lys Thr
 240 245 250

25 cgg gag agc agc ctg aag cgc agg cta ttc cga agc atg ttc ctg tcc 999
 Arg Glu Ser Ser Leu Lys Arg Arg Leu Phe Arg Ser Met Phe Leu Ser
 255 260 265

30 act gct gcc aca gcc cct cca agc agc agc aag cca ggc cct cca cca 1047
 Thr Ala Ala Thr Ala Pro Pro Ser Ser Ser Lys Pro Gly Pro Pro Pro
 270 275 280

35 cag agc aag ccc aac tcc tct ttc cga ccg ccg cag aaa gac aac ccc 1095
 Gln Ser Lys Pro Asn Ser Ser Phe Arg Pro Pro Gln Lys Asp Asn Pro
 285 290 295

40 cca agc ctg gtg gcc aag gcc cag tcc ttg ccc tcg gac cag ccg gtg 1143
 Pro Ser Leu Val Ala Lys Ala Gln Ser Leu Pro Ser Asp Gln Pro Val
 300 305 310 315

45 ggg acc ttc agc cct ctg acc act tcg gat acc agc agc ccc cag aag 1191
 Gly Thr Phe Ser Pro Leu Thr Thr Ser Asp Thr Ser Ser Pro Gln Lys
 320 325 330

50 tcc ctg cgc aca gcc ccg gcc aca ggc cag ctt cca ggc cgg tct tcc 1239
 Ser Leu Arg Thr Ala Pro Ala Thr Gly Gln Leu Pro Gly Arg Ser Ser
 335 340 345

55 cca gcg gga tcc ccc cgc acc tgg cac gcc cag atc agc acc agc aac 1287
 Pro Ala Gly Ser Pro Arg Thr Trp His Ala Gln Ile Ser Thr Ser Asn
 350 355 360

60 ctg tac ctg ccc cag gac ccc acg gtt gcc aag ggt gcc ctg gct ggt 1335
 Leu Tyr Leu Pro Gln Asp Pro Thr Val Ala Lys Gly Ala Leu Ala Gly
 365 370 375

EP 1 085 093 A2

	gag gac aca ggt gtt gtg aca cat gag cag ttc aag gct gcg ctc agg	1383
	Glu Asp Thr Gly Val Val Thr His Glu Gln Phe Lys Ala Ala Leu Arg	
5	380 385 390 395	
	atg gtg gtg gac cag ggt gac ccc cgg ctg ctg ctg gac agc tac gtg	1431
	Met Val Val Asp Gln Gly Asp Pro Arg Leu Leu Leu Asp Ser Tyr Val	
	400 405 410	
10	aag att ggc gag ggc tcc acc ggc atc gtc tgc ttg gcc cgg gag aag	1479
	Lys Ile Gly Glu Gly Ser Thr Gly Ile Val Cys Leu Ala Arg Glu Lys	
	415 420 425	
15	cac tcg ggc cgc cag gtg gcc gtc aag atg atg gac ctc agg aag cag	1527
	His Ser Gly Arg Gln Val Ala Val Lys Met Met Asp Leu Arg Lys Gln	
	430 435 440	
20	cag cgc agg gag ctg ctc ttc aac gag gtg gtg atc atg cgg gac tac	1575
	Gln Arg Arg Glu Leu Leu Phe Asn Glu Val Val Ile Met Arg Asp Tyr	
	445 450 455	
25	cag cac ttc aac gtg gtg gag atg tac aag agc tac ctg gtg gga gag	1623
	Gln His Phe Asn Val Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu	
	460 465 470 475	
30	gag ctg tgg gtg ctc atg gag ttc ctg cag gga gga gcc ctc aca gac	1671
	Glu Leu Trp Val Leu Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp	
	480 485 490	
35	atc gtc tcc caa gtc agg ctg aat gag gag cag att gcc act gtg tgt	1719
	Ile Val Ser Gln Val Arg Leu Asn Glu Glu Gln Ile Ala Thr Val Cys	
	495 500 505	
40	gag gct gtg ctg cag gcc ctg gcc tac ctg cat gct cag ggt gtc atc	1767
	Glu Ala Val Leu Gln Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile	
	510 515 520	
45	cac cgg gac atc aag agt gac tcc atc ctg ctg acc ctc gat ggc agg	1815
	His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg	
	525 530 535	
50	gtg aag ctc tcg gac ttc gga ttc tgt gct cag atc agc aaa gac gtc	1863
	Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val	
	540 545 550 555	
55	cct aag agg aag tcc ctg gtg gga acc ccc tac tgg atg gct cct gaa	1911
	Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu	
	560 565 570	

5
10
15
20
25
30
35
40
45
50
55

1959
2007
2055
2103
2151
2199
2244
2304
2364
2424
2484
2544
2604
2664
2669

EP 1 085 093 A2

<212> PRT

<213> Homo sapiens

<400> 10

```

Met Phe Arg Lys Lys Lys Lys Lys Arg Pro Glu Ile Ser Ala Pro Gln
 1          5          10          15
Asn Phe Gln His Arg Val His Thr Ser Phe Asp Pro Lys Glu Gly Lys
          20          25          30
Phe Val Gly Leu Pro Pro Gln Trp Gln Asn Ile Leu Asp Thr Leu Arg
          35          40          45
Arg Pro Lys Pro Val Val Asp Pro Ser Arg Ile Thr Arg Val Gln Leu
          50          55          60
Gln Pro Met Lys Thr Val Val Arg Gly Ser Ala Met Pro Val Asp Gly
15 65          70          75          80
Tyr Ile Ser Gly Leu Asn Asp Ile Gln Lys Leu Ser Val Ile Ser
          85          90          95
Ser Asn Thr Leu Arg Gly Arg Ser Pro Thr Ser Arg Arg Arg Ala Gln
20          100          105          110
Ser Leu Gly Leu Leu Gly Asp Glu His Trp Ala Thr Asp Pro Asp Met
          115          120          125
Tyr Leu Gln Ser Pro Gln Ser Glu Arg Thr Asp Pro His Gly Leu Tyr
25 130          135          140
Leu Ser Cys Asn Gly Gly Thr Pro Ala Gly His Lys Gln Met Pro Trp
145          150          155          160
Pro Glu Pro Gln Ser Pro Arg Val Leu Pro Asn Gly Leu Ala Ala Lys
          165          170          175
Ala Gln Ser Leu Gly Pro Ala Glu Phe Gln Gly Ala Ser Gln Arg Cys
30          180          185          190
Leu Gln Leu Gly Ala Cys Leu Gln Ser Ser Pro Pro Gly Ala Ser Pro
          195          200          205
Pro Thr Gly Thr Asn Arg His Gly Met Lys Ala Ala Lys His Gly Ser
35 210          215          220
Glu Glu Ala Arg Pro Gln Ser Cys Leu Val Gly Ser Ala Thr Gly Arg
225          230          235          240
Pro Gly Gly Glu Gly Ser Pro Ser Pro Lys Thr Arg Glu Ser Ser Leu
          245          250          255
Lys Arg Arg Leu Phe Arg Ser Met Phe Leu Ser Thr Ala Ala Thr Ala
40          260          265          270
Pro Pro Ser Ser Lys Pro Gly Pro Pro Pro Gln Ser Lys Pro Asn
          275          280          285
Ser Ser Phe Arg Pro Pro Gln Lys Asp Asn Pro Pro Ser Leu Val Ala
45 290          295          300
Lys Ala Gln Ser Leu Pro Ser Asp Gln Pro Val Gly Thr Phe Ser Pro
305          310          315          320
Leu Thr Thr Ser Asp Thr Ser Ser Pro Gln Lys Ser Leu Arg Thr Ala
          325          330          335
Pro Ala Thr Gly Gln Leu Pro Gly Arg Ser Ser Pro Ala Gly Ser Pro
50          340          345          350

```

EP 1 085 093 A2

Arg Thr Trp His Ala Gln Ile Ser Thr Ser Asn Leu Tyr Leu Pro Gln
355 360 365
5 Asp Pro Thr Val Ala Lys Gly Ala Leu Ala Gly Glu Asp Thr Gly Val
370 375 380
Val Thr His Glu Gln Phe Lys Ala Ala Leu Arg Met Val Val Asp Gln
385 390 395 400
Gly Asp Pro Arg Leu Leu Asp Ser Tyr Val Lys Ile Gly Glu Gly
405 410 415
10 Ser Thr Gly Ile Val Cys Leu Ala Arg Glu Lys His Ser Gly Arg Gln
420 425 430
Val Ala Val Lys Met Met Asp Leu Arg Lys Gln Gln Arg Arg Glu Leu
435 440 445
15 Leu Phe Asn Glu Val Val Ile Met Arg Asp Tyr Gln His Phe Asn Val
450 455 460
Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu Glu Leu Trp Val Leu
465 470 475 480
20 Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp Ile Val Ser Gln Val
485 490 495
Arg Leu Asn Glu Glu Gln Ile Ala Thr Val Cys Glu Ala Val Leu Gln
500 505 510
Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile His Arg Asp Ile Lys
515 520 525
25 Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg Val Lys Leu Ser Asp
530 535 540
Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val Pro Lys Arg Lys Ser
545 550 555 560
30 Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Ile Ser Arg Ser
565 570 575
Leu Tyr Ala Thr Glu Val Asp Ile Trp Ser Leu Gly Ile Met Val Ile
580 585 590
Glu Met Val Asp Gly Glu Pro Pro Tyr Phe Ser Asp Ser Pro Val Gln
595 600 605
35 Ala Met Lys Arg Leu Arg Asp Ser Pro Pro Pro Lys Leu Lys Asn Ser
610 615 620
His Lys Val Ser Pro Val Leu Arg Asp Phe Leu Glu Arg Met Leu Val
625 630 635 640
40 Arg Asp Pro Gln Glu Arg Ala Thr Ala Gln Glu Leu Leu Asp His Pro
645 650 655
Phe Leu Leu Gln Thr Gly Leu Pro Glu Cys Leu Val Pro Leu Ile Gln
660 665 670
45 Leu Tyr Arg Lys Gln Thr Ser Thr Cys
675 680

<210> 11
<211> 19038
<212> DNA

<213> Homo sapiens

<400> 11

```

5  tccccaccaa aaaattgtgc ccaagaaacc gtcgtgttcc cctgtgccaa ggtttcggtt 60
   ttaaagaaac cccccaaaca gggaaacctt ctttcttaaa ttgggttggt tgtgaacctt 120
   tcccttccaa gtcttgggca tccccccaaa tcaattcatg cgtagccaa ccagaaaaat 180
   gcctgcaacc atccaaaaga aaaaagttaa aagcagtctc accacaggca agtgcttttc 240
10  aagcttaggt tgaattctca agtgtgcctt cctccccctg tgtaagcca aagtttcagc 300
   cagaaggggc ttgggcctgt gcccaacctg cccacccccg ttttgcttg tttccacttc 360
   agggcttaag gctcacatca tctcttttca agctggcaag gagaaacggc agggctctggc 420
   tctctgaggg ggagtcctt tctttcttct tcntgggtgc tctttgtagg aaagctcctc 480
   ccctagatga attgcgtgca gatggagatg cttagagggc gacagtaaca gctggcatgg 540
15  cctgtttgac ttaaccttgq ggccccatgg ctggtgcagc agccacctcc ctacagcccg 600
   tggccttggg gacatggatg ggaaaaggag ccctggaaat ggcaagcggg ggccttggct 660
   gaccgggtgg gagtgtctct aggacacagc ctgatgctgg ggagaggcag ggcattgttt 720
   gtcctgggtg attcactcgc gatgactggg gcaacactgg tcccgttcag gtggatgaac 780
   gtctcttagg cactcagcct ccatggatca ctcttctctg tatttaaaaa tattttgttt 840
20  ttggccggac gcggtggctc acgcctgtaa tcccagcact ttgggaggct gaaggcgggt 900
   ggatcacctg aggtcaggag ttcaagatca gccagccaa catggtgaaa ccctatctct 960
   actaaaaata caaaaattag ccggacgtgg tggtgcacac ctatagtctc agctacttgg 1020
   gaggctgagg caggagaatc acttgaacct ggaaggcaga gggtgcagtg agccaagatc 1080
   gcaccactgt actccagcct gggcaacaga gtgaaacgct gtctcaaaaa aaaaaaaaaa 1140
25  aaaaaaaaaa tgtttttttt tagagaagca atccgtcgtc ttttaaggaa acttagaaaa 1200
   agagttagaaa gatagaatag aaggagatca cctgtagccc caccaggtaa atgggacaac 1260
   taatatgttg atgtatttcc ttcaaatagc cattgtattc aactgcatt gacaaattac 1320
   cattggcaaa atctttaaaa accccctacc cctaattctat atcatcaaga attccacttt 1380
   cgccaaagta aaccttgata gtttaatttg tgtctgggac ccatgactgt ggacagggtt 1440
30  agggcccagc aggtcgtggg atccaggaga gaccaccaa tcgggcccct cataatgatc 1500
   aactagacc tgaggggagt gagagtcagg ctacgggtac ccgccgtcac tcccaccagc 1560
   tttattattt tacctttcac attgaggttt gtgatctgtc tgcataattt tggagtatga 1620
   tatgagctca ttctccggg tttatttttt ttccatgcag atatcaaatt acttcagcta 1680
35  catttattaa aaacatcatc cattcccccga gcatgttgca gggtcacctt tgtcattaat 1740
   caaatgacct cataagagtg ggtctatttt tggattctct cttctgttcc attggtctat 1800
   ttgtcaattc cgtactaaat ttgccaattt ttgcctattt gcctattgcc tatttgccaa 1860
   ttccatacta aattaattat ttagcttttc taataaatct taatatctat ttagtacaat 1920
   cctccaactt cgttcattaa gattgtcttg gctattcctg gttctttata tttctgtata 1980
40  cattttagaa tcagttcatc aatttctacc aaaggaaata tgctgggatt ttgtttgaga 2040
   tttaaattaa tctgcagggt aacttgggaa taattgacat ctttacagta ttgaaccttc 2100
   tcactctatga acattcttta atatctttaa taatgttttg tattttccaa tataaggact 2160
   ttgtattttt ttgttagatt tattctagat attttgtatt tttaatgtaa aatgatatct 2220
   ttttaaaaaa ttcatTTTTT tttttgagac agagtctcgc tctgtcgccc aggctggaat 2280
45  gcagtggcct gatctcagct cactgcaagc tccgcctccc aggttcacgc cattctcctg 2340
   cctcagcctc ctgagtagct gggactacag gtgcccacca ccacaccggg ctaatgtttt 2400
   gtatgtttag tagagacggg gtttcaccgt gttagccagg atgatctcta tctcctgacc 2460
   tcgtgatctg cccacctcgg cctcccaaag tgctgggatt acaggcgtga gccaccgcgc 2520
50  ctggcccttt ttaaaaaatt catgttggtt ctggtatgta gaaatccagt tgatttttta 2580
   aaatattgac cttgagcctg ggcacgggtg ctcatgcctg taatcccagc actttgggag 2640
   gctgaggcgg gtggatcatg aagtcaagag atcgagacca tcttgccaa catggtgaaa 2700

```

ccccatctct actaaaaata caaaaattag ctgggcgtga tggcgtgcgc ctgtagtccc 2760
 agctactcag taggctaagg caggagaatc acttgaaccc gggaggcaga gattgcagtg 2820
 agctgagatc acaccactgc actccagccc gggcaagaca gcgagactcc atctcaaaaa 2880
 5 atatataat atatattgac ctggaatcag ggaccttcta aatlcactcc cttaatccca 2940
 gttttatgta gattctcccc cattttctac ttacacagtt atgttgtccc acacagtgtt 3000
 ggccctacca catttcagat gagtccatgc tgcctccctt taggtggttg attggttgat 3060
 tttccagacc taagtgatgg cctctggtt ctaaaagctct actccctagc ccccaaagcc 3120
 10 tgagctcagc tgattgcttc tgccaactcc caccctcacc atcaccactc ctggcccttg 3180
 gacaccctct gggctgtcct tctttcttct ccagcctccc tgctgcctct gggaagaact 3240
 tgttccggaa tggctcacta ttagaatgga ctcaagagag gctcccagag tcagagacca 3300
 tttgctaaag atgctctccc tgtgcatccc cacagcaaaa gctgagcgt tgggtggggc 3360
 aggggagttg gggagagggc tgtcttggyg tgggtggttg ggggcccgtt caccagctct 3420
 15 tcttcagctg cagtctgtgt ccctgcacct ccagaagatt tcacagagct agggaggag 3480
 gcgaacacag cagctcaact aatccaggga tagcaggtct atccaaggga ctgggggaat 3540
 agacctgtg aataaagact ctctgtagc aaaaggcaaa ggctgtaatc ccagcacttt 3600
 gggagaccaa ggcaggtgga tcatttgaa tcagaagtcc gagaccagcc tggccaacat 3660
 ggtgaaatcc cgtctctact aaaaatacaa aaattagccg ggtatgttg tgggtgcctg 3720
 20 taatctcagc tattcaggag gctgaggcaa gagaatcact tgaacccggg aggtggaggt 3780
 tgcagttagc ccagatgggt ccactacact ccagctctgg cgacaggcg gcaagactcc 3840
 ttctcaaaaa caacaacaac aacaacaaa aacaacaaa aaggcaaagg ccaaaaggag 3900
 gaggacaaat tttaacaaac catgatgtat atatggcgag gtccccaggt cccagacccc 3960
 tgacatcagg catgacccct ttgactggt agtctgagca gaaagtgggt tgggtgttact 4020
 25 cccagacttg tatctgcccc agtgccagt tctggagggc ctgagcttca agacagggat 4080
 tcaaaagag gtagacatcac aagagaaaca accgtcatgt atggggactc tgcttacttc 4140
 acacacccta aacctatga gctgtcttcc attaaccccc ctggctcaga tcatttcagt 4200
 tatttgttca aaatctctcc aaattatrag tgggagactc cctacaactc atctgcaact 4260
 30 cacacaggtt gttttattcc aaagggtctg gtctgtaagg gtccgttaca tgtggctcta 4320
 cctctagggg gtgttcgggt gatcccgaac ctcaagacct agaagcatgg ctgacattga 4380
 gatgtgacgt gggctctgat tgagtcacgc atggtgaatt cctagtgggg aacctaggc 4440
 tgccagggt ccctgccttt ctgccagctg cctccagat ctgcgacctc cttcagaacc 4500
 tgccaaaatg actaggaaaa tgctgtttcc atagcaagag ccaaaagaga acatgacggc 4560
 35 cctgcactcc agatcttcgg gcggatgagt aatccaagct ttcagttcaa gaatcatgtt 4620
 tcagtttctt gaagcctgga agtgacctt tcagatacat aagaacctag tgagctgttc 4680
 tgagcctctt cagatccaaa agcattcaag aggcagccct ggccctgtct gccatcaaca 4740
 tgtgatccca ggtccgggat cccctgaagg cgaaactaga gcaacccttt ggaagtgtcc 4800
 40 ctccccttcc caggccccc gttcccact ctgagatcta cccatgctat ccattgcaag 4860
 cctgtgtcac ttctgtgtat gcagctcagc acgaccttag gcaaagccag aatcagcaag 4920
 gcacgggaca caggcttgat tgcaggtraa gtgttttatt gtttgtttt tgagacagag 4980
 tctcattctg ttgccaggc tggagtgcag tggggcaatc tcagctcact gcagcctcag 5040
 cctcctgggt tcaagcgatt ctctccctc aaccctatgg gtatccggga ctacaggcac 5100
 45 gtgccaccag gcccggttaa ttcttttcta tttttagtca agacaggtt tcacctgtt 5160
 ggcaaagctg gtctcaaaact cctgacctca ggtgatccac ccgctcggc ctcccagagt 5220
 actaggatta caggcatgaa ccacctgcc cggcccagg gatgttttac atagagctcc 5280
 aataccagag agaagagtgt caaggggag tgggtgctct tgccttctct ggagagcttt 5340
 acccctaagt tagctgcccc tcaccacccc caggctatcc tcttggtca gggcctttct 5400
 50 ggaattgagg taaagcacat ggtaacattg aaggcccttt gggggctccc tgatacataa 5460
 tagtcccaca cggggcagca tgtctgtgat cagctggttg gctttttatt aacgtatcat 5520
 attaacaggt tcaaccatcc tgggacaaag ctgagttgta ataaaaaaa aaagccaaca 5580

EP 1 085 093 A2

. .
 5
 . .
 10
 . .
 15
 20
 25
 30
 35
 40
 45
 50
 55

aaaaaataac ttaatatatac tgttggaattc aattcgatag ttttaagatt ttcatagtta 5640
 cgttccctaaa tgatattgag tcaaattttc cttttcttgc actctcctta tctggtttta 5700
 agaatcaagg tcatactcgt ttcataaaac aagcttgcta actttcctcc ctctttcccc 5760
 atttttaaaaa ttcgttgaca gacagtggaa tgatacttgt aatgggcttt ggattttata 5820
 aaaacacacc cccagagtct gctgctcca taggggactt ggacagggca agaagacacc 5880
 tcttttctct gtttatagtc tgcactggct tatttatggc acgtttgttg tttctgggac 5940
 tgttctgctg ggagccagcc atttccctga ggaagcagag atgaagggtgc aggcaagccc 6000
 taggcttcta ggggagctgt gctgggggag gggagggagc cctgaacctg gtgccccagg 6060
 ccctgctgca gccacccctc tttcccggga gggagctcaa ccttactctg cacttacagg 6120
 caccatgttc cgcaagaaaa agaagaaacg ccctgagatc tcagcgccac agaacttcca 6180
 gcaccgtgtc cacacctctc tcgaccccaa agaaggcaag tttgtgggac tccccccaca 6240
 atggcagaac atcctggaca cactgcggcg ccccaagccc gtggtggacc ctctcgcaat 6300
 cacacgggtg cagctccagc ccatgaagggt aagagggggc ggaggggatg aggttcagcc 6360
 tctcccagta ctcagacaac catgcctggc taaacctcag aaaggccctt ggaggaacca 6420
 cctacttcac agctatcagt taatcagctg ttttaactcc ctgcctgtca gcctgccatt 6480
 ctctccctgg gtaagccagg gcgaaggagg ctggggagac cctctctgca ggggtggtgg 6540
 gttgccagat tcagcacatg aaaatgtgag atgctcaatt gcatttgtat ttcagatgac 6600
 aacgaatagt ctttttaggac gtgtccatt caatatgttg acctgcagcc ccataaggac 6660
 tgagggctct cccagaccag gagaattttta gttgtgaggg tcacgactag tagaccacaag 6720
 agcctggtag aaggtgggtg caggggcccct atcagggttt ggaggtgctg aagccagtgt 6780
 gtgtggaggga gccccggccc tgggtgtctc tectcagagg gctgggcaca tctctcccag 6840
 ccaccctgtg agctagagaa tggagccccc cccctgagc tccagctccc tggcccagcc 6900
 gaccacaccc ctgggcatgc tggatgcagc cccatggcac tcaccatctg ctctgctgac 6960
 gctgggcccct ctccccgcat ccctgcatcc agcacaggcg ggacccacgg tgggcccctg 7020
 taaattatg aaaaattaat ggggtgatga cacagcaggg aaggtcctta ggtggtcctc 7080
 cccagggccc ccagggacat tctctgacct tgatctccca gccacccctc cctgccacaa 7140
 ttgggcagct cccacacact cttttctctt cccctacag acagtgggtg ggggcagcgc 7200
 gatgcctgtg gatggctaca tctcggggct gctcaacgac atccagaagt tgtcagtcac 7260
 cagctccaac accctgcgtg gccgcagccc caccagccgg cggcgggcac agtccctggg 7320
 gctgctgggg gatgagcact gggccaccga cccagacatg tacctccaga gccccagtc 7380
 tgagcgcact gacccccacg gcctctacct cagctgcaac gggggcacac cagcaggcca 7440
 caagcagatg ccgtggcccg agccacagag cccacgggtc ctgcccattg ggctggctgc 7500
 aaaggcacag tccctgggccc ccgcccagtt tcagggtgcc tcgcagcgct gtctgcagct 7560
 ggggtgcctgc ctgcagagct cccacaccag agcctcgccc cccacgggca ccaataggca 7620
 tggaatgaag gctgccaagc atggctctga ggagggcccg ccacagtcct gcctgggtgg 7680
 ctacggcaca ggcaggcccag gtggggaagg cagccctagc cctaagaccc gggagagcag 7740
 cctgaagcgc aggtctattcc gaagcatggt cctgtccact gctgccacag cccctccaag 7800
 cagcagcaag ccaggccctc caccacagag caaggttaagt caggagcctg gcctgcaggt 7860
 gtccactggg gagtgggtgt agggacacag gccttgccca gccttcccct tggaggactg 7920
 gcaaagaggc tccctggact gcttccgcct aaggcggcag aaatgtgcac ggtaacctct 7980
 tctctaagga ggggtggctc cctcctcct ccttccctt ctttctctgt 8040
 gctgttgtgt tgtttcccat ttctgtcagt atttgttccc aagtgtgtgg ccataaggaaa 8100
 agctggattt gcctagtcca ggggcagcag gaggccgact tgtggcatgt gtgactgctt 8160
 cagacgcaca tttttcttgt gagaaaggaa aggggtgaag gagccccgt ggtgacattt 8220
 ctggcaggc agagtggagc gcacctttt gcttcttcca ggccctccag catcctgttg 8280
 atagtgcag taacctcttt tcccatattg cagaggagga gactgataga gagagggtga 8340
 gtcaccccca ggcctgatgg agagtgaatc agagaaggaa ggtggggagt gctctggggc 8400
 tgctgtccg gcccgggccc tcttggtcca tgactcttgc gtatgaaggc tttacaagca 8460

EP 1 085 093 A2

cagcagccac ttgttcttta gtccttccct gggaggggtca aaggcagtc taagaaacgg 8520
ctgctgacag tggcatgggt aatggagcct cccctccctc ctgggagggc ttttaagacaa 8580
gcctgggtac tcccctgtca tcggtggggt gagtgtggcc cagcctgcac aggggtgtggg 8640
tttggggatg acccggacta caacctctct gggtcactgc ctgccagctg aggtactcag 8700
agaaaagtct gggcgccgc gcgtgggtgc tcacgtctgt agtcccagca ctttgggagg 8760
ccaaggtgga lgggtcacga ggtcagyaga tcgagaccat cctcgctaac acggtgaaac 8820
cccgtctcta ctaaaaatac aaaaaaatt agccggcgcc ggtggcgggc gcctgtagtc 8880
caagctactc aggaggctga ggcaggagaa tggcgtgaac ccgggaggca gagcttgccg 8940
tgagctgaga tcgcaccact gcactccagc ctgggggaca gacagagcga gactccgtct 9000
caaaaaaaaa agagaaagtt ctgagctttg tgcactctag tcccctacta ggttaaagga 9060
cagtgggttg ggtaccccat ggggtgtggc ttgatgtatc tgtgagagga acacgagcat 9120
ctgtgagctg cagggtgtct ggaaggctgt gcccctgggg agactcagcc agaaaaccaa 9180
cgtaagatca ggacagtcca cctgctggg aaggtgagat tcggagcttg acctccctct 9240
gtctctcagg agtcctgtcg cgagccctca gggatttggg gaaaggggtt gtcaacactg 9300
ggctgggcac tcatttgcac ctttctgggc tcctgccagc accccacagc agggggagag 9360
gcctgtccat ccttgacaa tgtactgagt actcaccatg ggccactgct gctgggtatg 9420
ccgggatgtc cccatactt gtgggagcag gcggtagtta tctcgagctc agcaaaccca 9480
tacttccaaa tccaggggag tggtttccct ctgggcaact cagacacatc tttcaagatt 9540
tctactctga agccaagcct ctcaatggca agctgagacc ccccgagctg ctccgggccc 9600
gggcttctca gcgtctcac tgcaggcgct caggtcagtc catcctttgt ggtgggctct 9660
ccttgactg tagcagcctc cctggcctct actcactaga agttgggtgt acctcgggtt 9720
ggaataacca aaaatgcctc cagacactgc caaatgtcac tcgagcacac ccattaagaa 9780
ccactgcctt aagcaaattc aataacagat ggggagcatc agccttcctc ctctcctcc 9840
accaccacct accccaggag tcccagatc aagccagcag cccttgccac tggggctgac 9900
tctggacact tgcagcagct tccataacag cagttaggcc acagaggcca tgcagtgtgc 9960
caggcatggc tgcaggaggg tctgagtata gactccaggg ctctgtacc tagccccagg 10020
cagtgaggcc tggagtact ctgactaaag agatcaggaa gacaggcgct gggggcacag 10080
agaccaaaga ggcaagacag ttttttagga gcttgccagg attagacatg ttccacttag 10140
agtcagaagg gcaaacattg gttaagcacc taccgtgtac tccgatatat gtcaaggata 10200
catggcacca gtgggattgc agcatgggag tcagcagcca cgggcgtcct gcgggttcca 10260
gtgctacag gacaaccaa caaccacag ggttatgagg attacatgag atagtacgtt 10320
gaaggcactt gtcaaagtgg taagccctca ataatggct ttattagtag tatttgagat 10380
ggcgtctccc tctttcgccc aggctggagt gcagtggcac aatcttggct cactgcaacc 10440
tccacctcct gggttcaagt gatcctccca ccttagcctc ccaagtagct gggattacag 10500
gcacgctcca ccatacccaa ctaatttttg tatttttaga agagatgggg tttcaccatg 10560
ttgcccaggc tggctttgaa ctctgacct caagtgatcc acctgccttg gcctcccaa 10620
gtgctgggat tacaggcacc tgagccacca tgccaggccg gctttattat ttttaaaaat 10680
attatgccat ggccctctccc ctttaggata ctttaaggat agccccctaa gccacagct 10740
ggggagccat ggctcagggc gggaaatgag gcattgctgt aaatgtatgc atgactctc 10800
tagtggcttt cttcccaaga ggtctatcac atgagtaact tcagaattaa tccagagcct 10860
gtaacaatta attaattctg ttgtcgtgtc cccctttccc tttcttgtgt ggcctcaca 10920
gtttcatctg gtccttgctt gtgattacat tgataaaagc tccctccctg tggagacagg 10980
cagtgaagcc aacgaaagga tgctagagac cagacctgc cagqctgaa accaagccag 11040
ctccccagac tccccagcct atgtcccaga ctctgcttgt gctgggctcc tggctgggcc 11100
atccctccc cagcctccag acgcaggctc cgccctgagc ccagccagca cctgcagcag 11160
cagcagcagc acagggacct ggccgtgtga gacagggaag aaaccctac ctcagcctgt 11220
ccacgtggtc cccacacatc ctcagagtag agctggccca tgcagaagcc ctcaaggcca 11280
ggaggggaat gatctcattt tacagcctt cttaggagct tcaggatgag aggtcatcag 11340

EP 1 085 093 A2

agccacctca ggaggagctt taggtggtcc ccaagcttct gccccgaccc acctggatgg 11400
 gtgcctggag agcatgtttt ctgagttaag tccacactca ggccagcagg cagcttcctt 11460
 5 agagccccga gcctttctac aggttgactg tgtgatgcag tgagccctgc cccacttccc 11520
 tccctgtccc tgccctggtga cgtctcatgg aacctctgtt cccaggacct ggtatcacag 11580
 cctcagtcac ggccatgcgc cctccacccc cctcacagcc ctcccagagg ctccctgagg 11640
 ccgtaagatc atactgcccc cttatgcaga gtttctcaaa gtatgttcca tgggcctcct 11700
 aggaaccagg gaccttgctc aaatgcagtc tctgctctag gctcccaccc aatcaggctc 11760
 10 tgaggcgagg agtctgcggt ttctctagct cccagatct ctgcacacgt ccctgcattg 11820
 tagtgagagc aggtcagag aggatgactt gcctaaggct catcacaggg cagagcagcc 11880
 cagggtcggg ccccaggctc tgacagcccc gtccaggggt cccactgctc cactacacag 11940
 tggatggtga cagtgtcaca gtgtcacagt ggatggtgac agtcaggctc tggcgaggac 12000
 atgggagaaat gtttactgtc caaatgtact catcagggat ggagtgaagc caggcagctc 12060
 15 tgggaggatt gctagcttct ttctctgtaa ggtcaagcac acactcgggt gggcaggcag 12120
 gtgtgggggt ggcagaagtc tgccccagca tggtctcgg ccagcaggag tgccatttcc 12180
 accctaagca ggccagggac ttggctggag agtagaagcc ctgaagctgc ggggggtcgg 12240
 ggaaggaaag gagtggagggt tgccaaaagc actgaaaaga ctctggtggg gcccaaggcc 12300
 cagatcttggg gtttggggtc cctgagcaag catcccagcc caaacttact gcttgagatt 12360
 20 tcctgtaagt tgtttcagct atgggatcag gaccaggacc cactgggcac ctaagacaat 12420
 ggcttacatg atgggtttgg agaagttcct agaaggcttt ttctgcatcc cctgaagcat 12480
 ccctctccag gtgccttta aaaacacgta atccctggga ggggtcatgg tgcatatcac 12540
 cgctccttgg ggagaaccca aagatggcg ggacctttc ctgtcagaaa gagcagaagg 12600
 gcttgggctc gggaaagcaa gaagcctcgc aggtctccag ggctgggctc gagcagggct 12660
 25 cactgggggc ccaggctgcc cctcagctcc accttccctt cctccctccc tgccagagcc 12720
 aatgaggata gggcccttac ctctcctcc ctcccgggg ctcttagcc aggagtcca 12780
 tgccagggag gaagtggaaag gactccttta ggggtcctt aagacatctc cccatccctg 12840
 gcctcaaggc ttgggtttgg ctggacctac cctcctaact ccagatctct ctggcaccag 12900
 30 attcccagcc caggggagac acctgagaac ccccagatg gtgacacacc tctgtggtcc 12960
 tctgtcaggg acataacctc ccagcacaga ttgcaaaact ccctgctgca ggcacaggca 13020
 gggctatcgg gcccagggtg tggctccctt gccttggttc agggagtggg gacacagttg 13080
 cccactgctc cccaccccac tgccaggcct ctctgcccc catgggtcct ggggtggggg 13140
 agccttgagg gtgaagaatg cctctgaccc agattcttca agcagcctct gagctcagag 13200
 35 gaagagtctg cctcaaggca gcctccctgg ggtctagctg tcaatcgccc aggaagaaat 13260
 acccagcgca ggacccggcg gggagctggc ctctctgtc ttcccagggt cagcagagcg 13320
 agtgtaaggga gctgtcttgg gcctgccag cctgggtgcc tgcgggggac tgctggcaca 13380
 ggactgtgac tgggcttcag ctctgtctga aaatctttgc tcagagcacc tccctagtct 13440
 gatctgatac ccgcctgac cctgccagag tccagaggtc acggcgggca gcccctgcct 13500
 40 ccgggaagggt tattccaaat gctcccacag ccctgaccct tcctgttctt ttgtccctgc 13560
 agcccaactc ctctttccga ccgcgcgaga aagacaaccc cccaagcctg gtggccaagg 13620
 cccagtcctt gccctcggac cagccgggtg ggaccttcag ccctctgacc acttcggata 13680
 ccagcagccc ccagaagtec ctccgcacag ccccgccac aggcagctt ccaggccggg 13740
 45 ctccccagc gggatcccc cgcacctggc acgcccagat cagcaccagc aacctgtacc 13800
 tgccccagga ccccacggtt gccaaagggt cctgggtgg tgaggacaca ggtgttgtga 13860
 cacatgagca gttcaaggct gcgctcagga tgggtgggga ccagggtgac ccccggtgc 13920
 tgctggacag ctactggaag attggcgagg gctccaccgg catcgtctgc ttggcccggg 13980
 agaagcactc gggccgcca gtggccgtca agatgatgga cctcaggag cagcagcgca 14040
 50 gggagctgct cttaacag gtgggaggac aggtgggac acagacgggg gcgttgggga 14100
 tgggcagtga gcagccagcc aggtgggaca tctgtgagca ggggcagtgg gtggccatgc 14160
 gtctgggcac tgtgcctggc actcaggccc ccgctgccc ccagggtggtg atcatgcggg 14220

55

EP 1 085 093 A2

actaccagca cttcaacgtg gtggagatgt acaagagcta cctgggtgggc gaggagctgt 14280
 ggggtgctcat ggagttcctg cagggaggag ccctcacaga catcgtctcc caagtcaggt 14340
 gggcagctgg gagggtctga ccctgagtg caggctgccct caccatggcc ctgccagggc 14400
 5 aatgtggtct tctgcctgtg gcccaaga cttgggatgc ctgggctccc ctgcctgtg 14460
 gggtaactga gacccagggg tcttgggagt ggagaagaga aggatagctt ctaccgcaag 14520
 ctcaggcccc agttttcacc agggactcct cctgactgtg ctgccaaaca gattgcctgg 14580
 gagctgtggg gcctagcacc agggactcct actctgtcga gccacccac gacctgccag 14640
 10 agctaacgtt ctctttcatc ggggtggccc acccttcctgt ccaggctgaa tgaggagcag 14700
 attgccactg tgtgtgaggc tgtgtgtcag gccctggcct acctgcatgc tcagggtgtc 14760
 atccaccggg acatcaagag tgactccatc ctgctgaccc tcgatggcag ggtaggctccc 14820
 atcctgtccc tggcacagcc acgctccac ttcctcctga tccaccactc actccctttt 14880
 caaccgcagg tgaagctctc ggacttcgga ttctgtgtc agatcagcaa agacgtccct 14940
 15 aagaggaagt ccctgggtgg aacccctac tggatggctc ctgaagtgat ctccaggtct 15000
 ttgtatgcca ctgaggtaac cgttccctcc acccccaga cctcccaaaa gcaacttggc 15060
 aactggcagc tcttctgtg tggccctcc agtgagctca ccaaaagcag ccctggtttt 15120
 cagagtccca cctagtcac acccttcccc ctctcgatgg ggctgctctt acccagtgac 15180
 tttgctgcca ggaacgagtc ctgcaagtgc ttccctcagc tcaagggcag aatggggtat 15240
 20 ggccgggcct cctatgtatg atggcctttc tctgagtgc tgacagctgt gtccctatag 15300
 gcagtggcga ctcatgcagg cagtaactgg ccacagggca ggtgaccagg ggaggaagga 15360
 gacagacca ccaaggagag ctggggccag ctgtccccc tccaccactg ctgccaccag 15420
 aacgcagcta ccaatgggcc agggctctgg catggggtca gggacatttt cctcctgcag 15480
 25 gtggatatct ggtctctggg catcatggtg attgagatgg tagatgggga gccaccgtac 15540
 ttcagtact cccagtgca agccatgaag aggtccggg acagccccc acccaagctg 15600
 aaaaactctc acaaggtcag ttggcacaca aggggtgcgac ctgcgagacc ccattcctcc 15660
 tgaggcaagg ggaccagaac ctgggctccc agcatctccc ttccactgaa gccacagggt 15720
 ctgggctcct ggaagggtc cctctttccc cacacaaaac ccgcacctgg gtgtggagcc 15780
 30 gcatctacgc acaagtctgc atgtgcgtc cgacaagtgc cctcccacgg ctgtggcagg 15840
 agagtgtctg ctgggcagaa ggggtgtctg ttggcaggca ctggtcgga gccagtgagg 15900
 gcccctgagc agggaaagcc aggcaccag caatccctgc tgtccaggga gggatccgga 15960
 gaagcttac tgagcacaac cccttctaac ccgtgtcggg agatccatac catgattcga 16020
 35 tgtccctgtc catcagggc agtcggctca tgcctcatcg ttgcacccc cgacacagct 16080
 aagccacagc gttccctta aagccagtat aagtgcattg aagtgtatac atgtaaccct 16140
 ttttgccaaa tcggcccaa ccccgaggc ctactgtgg acgcccctg ctggcagggtc 16200
 agcacggggc tgctaagtgg caccgccatc tgggtggcaa aacaagaaat gtctcagagg 16260
 gctgaagcct ctccctctaa atagcaaaaa aacaagagtt ctgtggcccc aacacaaagc 16320
 40 tggatgggag gaccaacagg aaacatcttc caagacaact ggtccttggg gcccgaccg 16380
 ctaaccccaa aattagcata taaagatctc cagttggcta attcctcaga ggatgtagcc 16440
 ttctgcccaa gactcagcct catcccaaga tactggctca aaatgaacca agataagccc 16500
 ttgctttaga ctcttaaggc ctgagcaaac aaagaaatct tccttttcag gtctcacttt 16560
 attttctatt tttcagagta ctctctcatc ctgactgtt ttgtttctgt tgtgtttgg 16620
 45 tttttttttt tttttttttt tggagatgga gtctctctct gttgtctcagg ctggaatgca 16680
 gtggtgcgat ctgagctcac tgcaacctcc gcctcctggg ttcaagcaat tctcctgcct 16740
 cagcctcctg agtagctggg attacaggca cgtgccacca tgcacaaact atttttgtat 16800
 ttttagtaga gacagggttt cgccatgtt gtcaggctgg tctacgaact cctgacctcg 16860
 taactgtccc aacttggcct cccaaagtgc tgggattaca ggcttgagcc actgcgccc 16920
 50 gcgacctgtt tttaaaatct caaaagccct atgtggcaga cagggcaagc atactttatc 16980
 actagcccat tttacagatg agaaaactga gccttagaga aaactgtgac ttgcctgaga 17040
 tcacggatag agccagatct ggatcactga tgccaatcct ctgcccttc cacagagcta 17100

EP 1 085 093 A2

tagcatctga atgctgagag ccttgagggg gtggggaggg acaaggggaac aggaagttaa 17160
 aaaaccagcg aattcatgac ttccaacaa tgataagtcc aggcaatcag gtcaccccca 17220
 5 agtgactgca aattgtggct tcatcttact gccctgcctc tacaggtctc cccagtgtctg 17280
 cgagacttcc tggagcggat gctggtgctg gacccccaag agagagccac agcccaggag 17340
 ctccatagacc acccttccct gctgcagaca gggctacctg agtgccctgtt gccctgtatc 17400
 cagctctacc gaaagcagac ctccacctgc tgagcccacc ccaagtatgc ctgccacctc 17460
 cgcccacagg cagggcacac tgggcagcca gcctgcgggc aggaattgcc tgcctcctcc 17520
 10 tctcagtatt ctctccaaag attgaaatgt gaagcccag cccaccctc tgcccttcag 17580
 cctactgggc caggccggac ctgccccctc agtgtctctc cctcccaggt ccccagatgg 17640
 agacccttt ctacaggatg accccttgat attgcacag ggatatttct aagaaacgca 17700
 gaggccagcg ttctggcct ctgcagcaa cacagtagaa aaggctgctg tggtttttta 17760
 aaggcagttg tccactagtg tccataggca ctgcagaggg cagactgctg gtctccacag 17820
 15 atacctgtctg ttctcagctc cagcttcaaa cctcaggtct cgagagggcc acgggggtgtg 17880
 ttttatgacc ggaatcccgc ttctccctc acgtctgatg tccgaagggt gcagctccac 17940
 ctgtacagcc cctccccgcc cagaactgtg aatggcctgc tccaggccat ggctgggggc 18000
 agggagtgag gggacaattt ctgagtgaag gagaaagaat ggggtcgggt gtgaagggtg 18060
 tctcacttta cagaatggag agaactcgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 18120
 20 gtgtgtgttaa ggggaggaag gccacctga cagcccaggt cctccaggt caccacacag 18180
 cagtttcagg aaggctgccc ctctctccca ctaagtctg gcctgaagggt acctgtcttc 18240
 ttggcctggc ttccacctct cactcctgt gtctacctgg ccagtggagt ggtccatgct 18300
 aagtctaaca ctctcgggag ctccaggaggc ttctgagctt ctctgtact gtgcatcgtg 18360
 25 agggccagag acaggaatgt aaggattggc aactgtgtta cctttcaagt ttatctcaat 18420
 aaccaggta tcagggaccc attgttctct tcagaaccct atctgggaga gaaggcgaac 18480
 cacctccggg ttccatcat gtcaaggtca caggcatcca tgtgtgcaaa ccatctgccc 18540
 cagctgcctc cacagactgc tgtctccttg tctcctcgg cctgccccca ctccagggt 18600
 gctgtgagat ggaattccag gaaagaactt caggtgtctg gacctttct atctagataa 18660
 30 tatttttaga ttctctgtct ccctagtgtg ctacctggg gcaaagaaat tgcaaggact 18720
 tttttttaag ggtcagagtt ttcaaaacaa aagcatcttc cctagaaatt ttgtgaatt 18780
 gtttgcaact gtgcctgttt taaattaaat tgagtgttca aagccattgg gcttccctgtg 18840
 tctctgggag cggagaccgg ccgtcttgga ggggggtctc ctgtggcggg tgaatctcgt 18900
 gtagcctccc ctctcccca cgtgagctct ccagcagcca caccacagaa caccacaatt 18960
 35 ccctggtggc ctgtggaccc gaaaggaggg cagagaggaa gggaaacagg aagtgaagg 19020
 cccttgggaa tgaaggcg 19038

40 <210> 12
 <211> 146
 <212> DNA
 <213> Homo sapiens

45 <220>
 <221> CDS
 <222> (2)..(145)

50 <400> 12
 g cac cgg gat atc aag ggg cag aat gtg ctg ctg aca gag aat gct gag 49
 His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu Thr Glu Asn Ala Glu
 1 5 10 15

55

5

10

15

20

25

30

35

40

45

50

55

<213> Homo sapiens

<400> 16

cccgaattca tgcamcanga yathaar

27

<210> 17

<211> 29

<212> DNA

<213> Homo sapiens

<400> 17

cccgaattcg cnacytcngg ngccatcca

29

<210> 18

<211> 17

<212> DNA

<213> Homo sapiens

<400> 18

gagtgactcc atcctgc

17

<210> 19

<211> 17

<212> DNA

<213> Homo sapiens

<400> 19

gtaggggggtt cccacca

17

Claims

1. An isolated polynucleotide molecule comprising a nucleotide sequence encoding an MLK4 gene product from a human, wherein the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2.
2. The isolated polynucleotide sequence of claim 1 comprising the nucleotide sequence of SEQ ID NO:1.
3. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:1.
4. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding an MLK4 gene product from a human, wherein the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2.
5. The isolated polynucleotide molecule of claim 4, wherein the nucleotide sequence encoding the MLK4 gene product comprises the nucleotide sequence of SEQ ID NO:1.

6. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK4 gene product from a human, wherein the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4.
7. The isolated polynucleotide sequence of claim 6 comprising the nucleotide sequence of SEQ ID NO:3.
8. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3.
9. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding a PAK4 gene product from a human, wherein the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4.
10. The isolated polynucleotide molecule of claim 9, wherein the nucleotide sequence encoding the PAK4 gene product comprises the nucleotide sequence of SEQ ID NO:3.
11. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK5 gene product from a human, wherein the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10.
12. The isolated polynucleotide sequence of claim 11, comprising the nucleotide sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 from nt 199 to nt 2244, or SEQ ID NO:11 from nt 6125 to nt 17433.
13. An isolated polynucleotide molecule comprising the nucleotide sequence of an exon of SEQ ID NO:7.
14. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 from nt 199 to nt 2244, or SEQ ID NO:11 from nt 6125 to nt 17433.
15. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding a PAK5 gene product from a human, wherein the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10.
16. The isolated polynucleotide molecule of claim 15, wherein the nucleotide sequence encoding the PAK5 gene product comprises the nucleotide sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 from nt 199 to nt 2244, or SEQ ID NO:11 from nt 6125 to nt 17433.
17. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a YSK2 gene product from a human, wherein the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13.
18. The isolated polynucleotide sequence of claim 17, comprising the nucleotide sequence of SEQ ID NO:12.
19. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:12.
20. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding a YSK2 gene product from a human, wherein the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13.
21. The isolated polynucleotide molecule of claim 20, wherein the nucleotide sequence encoding the YSK2 gene product comprises the nucleotide sequence of SEQ ID NO:12.
22. A recombinant vector comprising any of the polynucleotide molecules of claims 1-21.
23. A transformed host cell comprising the recombinant vector of claim 22.
24. A substantially purified or isolated polypeptide comprising a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:13.

25. A method of preparing a substantially purified or isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:13, comprising culturing host cells of claim 23 under conditions conducive to the expression of the polypeptide or peptide fragment, and recovering in substantially purified or isolated form the polypeptide or peptide fragment from the cell culture.
26. An isolated antibody specific for a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:13.
27. The isolated antibody of claim 26 which is specific for amino acid residues 1-10 of SEQ ID NO:13.
28. A method of screening for compounds that affect the cellular levels of a JNKKK gene product, comprising:
- applying a test compound to a cellular test sample;
 - determining the cellular level of at least one JNKKK gene product in the test sample wherein the gene product is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:13 or an mRNA encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:13; and
 - comparing the levels of the gene product in the test sample with that in a reference sample;
- wherein a specific change in the cellular levels of the gene product in the test sample as compared to the reference sample indicates that the compound affects the cellular levels of gene product from a JNKKK gene.
29. The method of claim 28, wherein the gene product is an mRNA.
30. The method of claim 28 further comprising the step of applying a stress event to the test sample, and determining the effect of the test compound on the response of the test sample to the stress event.
31. The method of claim 28, wherein the stress event is exposure to ultraviolet radiation.
32. The method of claim 29, wherein the stress event is exposure to an inflammatory cytokine.
33. The method of claim 28, wherein the test and reference samples are cultured cells.
34. The method of claim 28, wherein the test and reference samples are cultured skin tissues.
35. The method of claim 28, wherein the test and reference samples are animals.
36. A method of screening for compounds that affect the activity of a JNKKK, the method comprising:
- applying a test compound to a test sample;
 - determining the activity of a JNKKK in the test sample and a reference sample, wherein the JNKKK comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:13;
- wherein a test compound that alters the JNKKK activity in the test sample as compared to the reference sample is identified as a compound that affects the activity of the JNKKK.
37. The method of claim 36, wherein the step of determining the activity of the JNKKK comprises determining kinase activity of the JNKKK.
38. The method of claim 36, further comprising the step of applying a stress event to the test sample and determining the effect of the test compound on the response of the test sample to the stress event.
39. The method of claim 38, wherein the stress event is ultra-violet radiation.
40. The method of claim 38, wherein the stress event is an inflammatory cytokine.

41. The method of claim 36, wherein the test and reference samples are cultured cells.

42. The method of claim 36 wherein the test and reference samples are cultured skin tissues.

5 43. A method for identifying a compound that binds to a PAK5 polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, or that binds to a YSK2 polypeptide comprising the amino acid sequence of SEQ ID NO:13, comprising:

- 10 a) contacting a test compound with the polypeptide for a time sufficient to form polypeptide/compound complex; and
 b) detecting the complex; so that if a polypeptide/test compound complex is detected, a compound that binds to the PAK5 polypeptide or YSK2 polypeptide is identified.

15 44. A method of screening for compounds that affect the expression of a gene that encodes a JNKKK gene product, comprising:

- 20 (a) applying a test compound to a test sample;
 (b) determining the expression level of at least one gene in cells of the test sample, wherein the gene encodes a JNKKK gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10 and 13; and
 (c) comparing the expression level of the gene in the test sample with that in a reference sample;

25 wherein a specific change in the expression of the gene in the test sample as compared to the reference sample indicates that the test compound affects the expression of the gene.

45. The method of claim 44, further comprising the step of applying a stress event to the test sample and determining the effect of the test compound on the gene expression response of the test sample to the stress event.

30 46. A method of detecting an MLK4-, PAK4-, PAK5- or YSK2-related polynucleotide in a sample, comprising contacting the sample with a compound that binds to and forms a complex with the particular polynucleotide for a period of time sufficient to form the complex, and detecting the complex, so that if a complex is detected, the MLK4, PAK4, PAK5 or YSK2-related polynucleotide, respectively, is detected.

35 47. The method of claim 46, wherein the method comprises contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the particular polynucleotide under such hybridization conditions, and amplifying the annealed polynucleotides, so that if a particular polynucleotide is amplified, the MLK4-, PAK4-, PAK5- or YSK2-related polynucleotide, respectively, is detected.




FIG. 1




FIG. 2





FIG. 3B

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.